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TRIM22 IS A NOVEL RESTRICTION FACTOR OF HERPESVIRUSES 
Abstract 
The host response to the family of nuclear replicating DNA viruses or the 
herpesviruses includes the intrinsic, innate and adaptive arms of the immune 
system. Intrinsic resistance is a constitutively active line of defense against virus 
infections and members of the Tripartite Motif (TRIM) superfamily of proteins; 
such as TRIM5 and TRIM19/PML in nuclear domain 10 (ND10) bodies are 
important restriction factors in this system. Nuclear intrinsic restriction against the 
prototypical DNA virus, herpes simplex virus 1 (HSV-1) includes interferon-
inducible protein 16 (IFI16) and ND10 bodies. However, the viral E3 ubiquitin 
ligase, ICP0, encoded by wild-type HSV-1, targets these intrinsic immune 
proteins for degradation.  
Previous reports on the anti-viral function of TRIM22, the human paralog 
of the prototypical TRIM5α protein, emphasized its role as a gene of the innate 
immune system, particularly its expression as a Type I and Type II interferon-
stimulated gene and its antiviral function against retroviruses. This study shows 
that TRIM22 has an additional intrinsic immune role against DNA viruses, using 
the herpesviruses as an example of a family of DNA viruses.  
We report that TRIM22 is a novel restriction factor of HSV-1 and limits 
HSV-1 ICP0-null virus replication. The TRIM22-mediated restriction of HSV-1 
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occurs after nuclear entry but prior to viral immediate-early gene transcription, by 
promoting histone occupancy and heterochromatinization to reduce immediate-
early viral gene expression. The ICP0-rescued virus evades the TRIM22-specific 
restriction by a mechanism independent of TRIM22 degradation. We also 
demonstrate that TRIM22 inhibits other DNA viruses, including representative 
members of the β- and γ- herpesviruses. These results collectively show that 
TRIM22 acts in the nucleus, and provide evidence that TRIM22 restricts HSV 
gene expression by promoting histone occupancy on the viral genes. 
Furthermore, we identified seven haplotypic variants of TRIM22 and 
propose that amino acid substitutions in the linker L2 domain and the coiled-coil 
domain of TRIM22 alter the magnitude of its restriction against the 
herpesviruses. Together, these results argue for the importance of the TRIM22 
gene as a restriction factor against herpesviruses and offer a novel avenue for 
further investigation on the role of TRIM genes in host genetic variation in 
herpesviral susceptibility.  
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Chapter 1:  
INTRODUCTION TO THE INNATE IMMUNE RESPONSE TO 
HERPESVIRUSES 
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It is almost certain that by the time humans reach adulthood, they have 
been exposed to a herpesvirus. The herpesviruses are a large family of viruses 
with linear dsDNA genomes that replicate in the nucleus of host cells. They are 
found throughout the metazoan kingdom in diverse hosts ranging from oysters to 
humans [1]. This successful co-speciation can partially be attributed to the viral 
gene products encoded by the herpesviruses. This helps the herpesviruses to 
co-opt the host anti-viral immune response during primary infection and establish 
latency in their natural hosts. The ubiquitous nature of these viruses combined 
with their ability for life-long persistence in hosts makes them a rich source of 
information on virus-host interactions. Other biological characteristics common to 
herpesviruses are their arsenal of enzymes important for nucleotide metabolism, 
DNA synthesis and protein processing, and the long-term lysis of infected cells 
upon the production of infectious progeny. 
 
1.1: Herpesviridae family and epidemiology 
The Herpesviridae family is divided into the Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae sub-families. Among the 
approximately 130 herpesviruses identified in the environment, 9 of them are 
human pathogens. Herpes simplex virus 1 (HSV-1), herpes simplex virus 2 
(HSV-2), varicella-zoster virus (VZV) are α-herpesviruses. Human herpesvirus 
type-6A, -6B, -7 (HHV-6A, HHV-6B, HHV-7) and human cytomegalovirus 
(HCMV) are β-herpesviruses. Epstein-Barr virus (EBV) and human herpesvirus-8 
(HHV-8) are γ-herpesviruses [2].  
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The α-herpesviruses, such as HSV-1, demonstrate a wide range of 
cellular tropism and their lytic replication cycle is well characterized in in vitro 
models. These viruses establish latency in the sensory ganglia of neurons. In 
humans, the two prototypical herpesviruses, HSV-1 and HSV-2, are known to 
cause diseases ranging from orofacial infections, to herpes labialis, to life-
threatening encephalitis [1]. As of 2002, an estimated 90% of the worldwide 
population has either one or both of these viruses [3]. The prevalence of HSV-1 
in adults is 65% in the United States [4] and 15.5% of non-Hispanic adults in the 
United States are seropositive for HSV-2 [5]. VZV is the causative agent of 
chicken pox during primary infection and causes herpes zoster or shingles upon 
reactivation from latency.  
The β-herpesviruses have a more restricted range of cell tropism relative 
to the α-herpesviruses, and replicate at a significantly slower rate in vitro. These 
viruses establish latency in cells of the myeloid lineage. HCMV causes disease in 
immunocompromised individuals and transplant recipients. HCMV can also 
cause severe congenital disease. In the United States, 1 in 750 infants are born 
with or develop permanent problems due to congenital CMV infection [6].  
The γ-herpesviruses have a restricted cell tropism and tend to establish 
latent, rather than lytic, infection in lymphoid cells. Consequently, the study of 
lytic replication cycle for these viruses is technically challenging. As an example 
of a γ-herpesvirus infection, EBV infects epithelial cells and resting B cells and is 
the causative agent of infectious mononucleosis. EBV has also been associated 
with various cancers including Burkitt’s lymphomas, a subset of Hodgkin’s 
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lymphomas, and nasopharyngeal carcinomas. Over 95% of adults worldwide 
have been exposed to EBV [7] and remain lifelong carriers of the virus. In 
addition, the geographic distribution of EBV-associated cancers offers evidence 
for host susceptibility to herpesviral disease. For example, the EBV-associated 
nasopharyngeal carcinoma shows high incidence in South-East Asia, northern 
Africa, Alaska and Greenland [8,9]. In addition, the incidence of EBV-positive 
Burkitt’s lymphomas is high in equatorial Africa, Papua New Guinea and areas of 
Brazil [10]. However, this ethnographic distribution of EBV-associated cancers 
may be due to additional confounding correlative factors [11]. 
In conclusion, a significant proportion of the population worldwide is at risk 
for diseases associated with the herpesviruses due to their high prevalence and 
the ability to remain latent or “hidden” from the host immune response. 
 
1.2: Herpesvirus replication cycles 
The herpesvirus virion is able to replicate and target the host immune 
response due to the following features: (i) the innermost linear dsDNA genome 
devoid of histones is surrounded by (ii) the viral icosahedral capsid composed of 
protein subunits enclosed by (iii) an unstructured, proteinaceous layer called the 
tegument and (iv) an envelope containing viral glycoproteins.  
 
1.2.1: HSV-1 lytic replication cycle 
The viral lytic replication cycle proceeds as follows: (i) Attachment or binding 
to the target cell (ii) Entry into the cell (iii) Repression and de-repression of viral 
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DNA (iv) Gene expression (v) DNA replication and (vi) Assembly and egress 
(reviewed in [12]).  
Attachment or binding to the target cell: The virion glycoproteins, gC and gD, 
bind to glycosaminoglycans on the target cell surface. This allows for the viral gD to 
interact with one of the natural receptors of HSV- nectins, herpes virus entry 
molecule (HVEM), and 3-O-sulfated heparan sulfate. The resulting conformational 
changes in gH/gL, followed by the activation of gB allows for the fusion of the viral 
envelope with the cell surface membrane. 
Entry into the cell: After the envelope fuses with the cell membrane, the viral 
tegument and the enclosed capsid core transits through the cytoplasm along 
microtubules to the nuclear pores. The capsids dock at the nuclear pores and the 
viral DNA is then released into the nucleus in cooperation with host cell factors 
including host nuclear factor importin-β and nuclear pore complex proteins. 
Although some of the viral tegument proteins have different intracellular 
destinations, the viral VP16 tegument protein enters the nucleus. 
Repression and de-repression of viral DNA: After nuclear entry, the viral 
DNA circularizes in a process mediated by the cellular DNA ligase IV/XRCC4. The 
host cell initially silences the viral DNA by assembling the free viral DNA into 
nucleosomes and initiating posttranslational modifications of histone tails to 
compact the chromatin to form heterochromatin. At later times during infection, the 
amount of chromatin associated with viral DNA is reduced and posttranslational 
modifications that reduce the compaction of viral DNA or euchromatin marks are 
increased. The viral tegument protein, VP16, de-represses the chromatinized viral 
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gene promoters with the aid of other cellular factors such as Oct-1, host cell factor 1 
(HCF-1), lysine-specific demethylase 1 (LSD1), a histone acetyl transferase, 
CLOCK (reviewed in [12]). 
Gene expression: The viral genes are transcribed in three waves, starting 
with the immediate-early or α genes, followed by the early or β genes and ending 
with the late or γ genes. The viral gene transcripts are exported out of the nucleus 
into the cytoplasm, where the host cell translation apparatus is hijacked to 
synthesize the viral proteins.  
The immediate-early genes are transcribed in the absence of de novo 
protein synthesis and include infected cell polypeptide (ICP) 0, 4, 22, 27 and 47. 
The expression of early and late genes requires ICP4. ICP0 is particularly 
important as it promotes the replication of HSV-1 in experimental systems at low 
multiplicities of infection, as evidenced by a 10- to 1000- fold defect in viral yields 
of ICP0-deleted mutant viruses [13,14]. At high multiplicities of infection, this 
defect in viral yields is not observed in transformed cell lines. The U2OS 
osteosarcoma cell line is the most permissive cell line for ICP0-deleted mutant 
viruses and therefore, is the standard cell line for readouts of the number of 
infectious viral particles comparing wild-type and ICP0-mutant viruses. ICP0 
transactivates both viral and non-viral gene promoters [15]. This is partially 
mediated by ICP0’s ability to derepress viral genomes and counter the effect of 
host histone deacetylases (HDACs). Furthermore, ICP0 is crucial to the switch 
between latent and lytic replication of HSV-1 [16].  
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DNA replication: The early gene products are components of the viral DNA 
replication machinery and productive infection; the early proteins such as ICP8 
reduce the expression of the immediate-early genes. The HSV-1 gene products 
UL9 (origin-binding protein), ICP8 (ssdNA binding protein), UL30/UL42 (viral DNA 
polymerase), and UL5/UL8/UL52 (helicase/primase complex) are all involved in 
viral DNA synthesis. Concurrent with viral DNA replication, the late gene products 
are transcribed and serve in the structural assembly of newly formed capsids. 
Assembly and egress: The nucleocapsids transit through the nuclear 
membranes by multiple hypothesized processes including primary envelopment at 
the inner nuclear membrane, followed by deenvelopment at the outer nuclear 
membrane. The resultant capsids are associated with tegument proteins, followed 
by envelopment in cytoplasmic organelles such as the trans-Golgi network. The 
enveloped virus is then exocytosed out of the cell.  
 
1.2.2: HSV-1 latent replication cycle 
 The HSV-1 latent replication cycle is not as well studied as the lytic 
replication cycle. Following the spread of HSV-1 at the primary site of infection, the 
virus infects sensory neurons. The nucleocapsid travels via the axonal termini to 
the nucleus where the viral DNA is maintained as extrachromasomal circular 
episomes, associated with nucleosomes. Instead of the lytic genes usually 
expressed in productive infection, the latency-associated transcripts (LATs) are 
produced. The virus undergoes reactivation or a return to lytic infection under many 
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conditions including stress and UV irradiation to the host. This reactivation can lead 
to a visual asymptomatic lesion.   
 
1.2.3: EBV lytic replication 
The lytic replication cycle of EBV is mostly informed by studies on 
reactivation from latency. Viral entry in epithelial cells occurs at the cell surface 
rather than through endocytosis. In addition to CD21, the EBV glycoprotein 
BMRF2 also mediates attachment to tonsilar epithelial cells. The viral immediate- 
early gene products, BZLF1 and BRLF1, are expressed in lytic infection. These 
proteins then induce the expression of the early gene products, BALF5 or the 
EBV DNA polymerase, BMRF1, and the ssDNA binding protein BALF2 (reviewed 
in [17]). The EBV genome then replicates in a rolling circle mechanism similar to 
HSV-1 DNA replication in discrete nuclear compartments. This is followed by late 
gene expression resulting in the production of viral capsid antigen, major capsid 
protein and glycoproteins. Linear individual units of viral genomes are assembled 
with the structural capsid proteins and the newly assembled nucleocapsids 
transit through the cytoplasm and exit the cells.  
 
1.2.4: EBV latent replication cycle 
Unlike HSV-1, EBV primarily undergoes the latent replication cycle in in vitro 
systems of infection. The ability of the virus to establish latency is closely tied with 
the number of EBV-associated cancers mentioned earlier.  
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Attachment: In B cells, the EBV virion glycoproteins gp350/220 bind to 
CD21, a complement C3d receptor, to tether the virus onto B cells. Further binding 
in B cells is mediated by the interaction between the viral gp42 and the cellular 
HLA-II (Including HLA-DP, HLA-DQ and HLA-DR) [18,19]. This is followed by 
fusion mediated by viral gH/gL and endocytosis of the attached virion.   
Transformation of B cells: After infection of B cells, the host RNA 
polymerase II transcribes viral genes. Early in viral replication, the Wp promoter 
drives the expression of the EBV gene products, Epstein Barr nuclear antigen-2 
(EBNA-2) and Epstein Barr nuclear antigen leader protein (EBNA-LP). The virus 
establishes different patterns of gene expression in stages designated as latency 0, 
latency 1, and latency 2. The major viral gene products expressed during this stage 
are EBV encoded RNAs (EBERs), microRNAs, Epstein Barr nuclear antigens 
(EBNAs) and latent membrane proteins (LMPs) found in cellular membranes.  
In latency 0, or the stage in which the virus is found in B-lymphocytes of 
infected patients, very few viral gene products are expressed. In latency 1 found in 
Burkitt’s lymphoma, only EBNA1 is expressed. In latency 2 found in 
nasopharyngeal carcinomas, Hodgkin’s lymphomas, T-cell lymphomas, EBNA1, 
LMP1 and LMP2 are expressed. In latency 3, the virus establishes latency in B 
cells, which get immortalized and proliferate as lymphoblastoid cell lines (B-LCLs). 
All the known latent genes are expressed in B-LCLs including EBNA-1, EBNA-2, 
EBNA-3A, EBNA-3B, EBNA-3C, LMP1, LMP2 and BARTs and EBV encoded 
RNAs such as EBER-1 and EBER-2. EBNA-LP and EBNA-2 reach stable levels at 
24-32 hours post infection (hpi), which are maintained in B-LCLs (reviewed in [12]).  
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Episome formation and maintenance:  The viral genomes are maintained in 
B-LCLs as multicopy, extrachromosomal, covalently closed circular DNA genomes 
called episomes in the nucleus during latency. These episomes are associated with 
chromatin in the form of nucleosomes and are maintained in stable copy numbers 
and passed to daughter cells through non-stochastic segregation by an EBNA1- 
mediated mechanism [20-23]. Besides EBNA1, proteins involved in the DNA 
replication fork protection, Timeless (Tim) and Timeless-interacting protein (Tipin) 
are essential for the maintenance of episomal forms of EBV DNA in latent cells [24]. 
 
1.3: Immune response to herpesviruses 
The immune response to the herpesviruses consists of the adaptive, 
innate, and intrinsic arms. The adaptive immune responses include cell-mediated 
immunity and antibody production. The innate immune response includes the 
induction of complement, activation of natural killer (NK) cells and macrophages, 
production of interferons (IFNs) by plasmacytoid dendritic cells (pDCs), 
conventional dendritic cells and macrophages. Prior to the induction of these 
various responses, the host response includes intracellular innate immune 
recognition of the herpesviruses. The innate immune sensing of HSV-1 is 
described below as a relevant example. 
 
1.3.1: Innate immune response to herpesviruses 
The patterns of the virus that are recognized as foreign, referred to as 
pathogen-associated molecular patterns (PAMPS) include proteins such as viral 
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glycoproteins and tegument; nucleic acids such as the GC-rich DNA genome and 
RNA [25]. The host cell has pattern recognition receptors (PRRs), which 
recognize these PAMPs, as part of the innate immune response. Examples of 
PRRs include members of the Toll-like receptor (TLR) family, NOD-like receptors 
(NLRs) and RIG-I like receptors (RLRs). This results in signaling mediated by 
adaptor proteins, the activation of transcription factors such as interferon 
regulatory factor (IRF) -3, -7, Activator Protein 1 (AP1) and nuclear factor κB (NF-
κB). Consequently, this results in the induction of Type I IFNs and other 
cytokines [26].   
Upon viral adhesion to the host cell, viral glycoproteins gH/gL and gB are 
recognized by Toll-like receptor 2 (TLR2), resulting in NF-κB activation and the 
production of pro-inflammatory cytokines in 293T cells [27]. Endosomal TLR3 
recognizes dsRNA and endosomal TLR9 recognizes unmethylated CpG DNA. 
This triggers the production of IFNβ, IFNλ and IL6.  
The viral DNA transitions through the cytoplasm where it is recognized by 
cyclic GMP-AMP synthase (cGAS) [28], DEAD (Asp-Glu-Ala-Asp) Box 
Polypeptide 60 (DDX60), DEAH (Asp-Glu-Ala-His) Box Helicase 9 (DHX9) [29], 
DHX36 [29] or Ku70, which leads to the production of cytokines such as Type I 
IFN. Viral DNA is also recognized in endosomes by TLR9 upon endocytosis in 
plasmacytoid dendritic cells. Upon nuclear entry, viral DNA is recognized by 
IFI16 resulting in the IRF3 mediated production of IFNβ [30] and caspase 
activation through a hypothesized inflammasome-mediated pathway [31]. 
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The prototypic member of the RIG-I-like receptors (RLRs) RIG-I, detects 
the 5’-triphosphate RNA transcribed from the HSV-1 DNA by RNA pol III. 
Melanoma differentiated gene 5 (MDA5), another RLR family member, 
recognizes higher order RNA intermediates in the cytoplasm transcribed from 
viral DNA resulting in IFNβ, IFNλ and TNFα production [32]. Therefore, it is 
evident that the host cell mounts a significant immune response against infection 
by DNA viruses.  
The importance of the intracellular innate immune response to the 
herpesvirus is evidenced by the fact that susceptibility to herpesviral diseases 
increases in hosts with mutations in genes of this pathway. Mutations in 
components of the TLR3 innate immune signaling pathway in young children 
aged 3 months – 6 years old increase the risk of recurrent herpesvirus 
encephalitis. These mutations in TLR3 [33], TRAF3 [34], UNC93B1 [35] and 
TRIF [36] genes are hypothesized to reduce the capacity of these patients to 
produce Type I IFNs. Interestingly, these individuals do not seem to show an 
increased susceptibility to other pathogens suggesting that the deficiency in the 
TLR3 signaling pathways is specific to herpesviral susceptibility in these patients 
[37].  
The importance of the extracellular innate immune response is evident in 
rodent models of herpesviral infections. Resistance to MCMV, a murine β-
herpesvirus, was attributed to the Cmv4 gene locus encoding the NK cell 
receptor, Ly49H [38]. The expression of Ly49H on NK cells of C57Bl/6 mice also 
contributes to the resistance of these mice to MCMV infection, whereas the 
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absence of the Ly49H receptor on Balb/c mice contributes to the susceptibility of 
these mice to MCMV. 
Despite the significant host immune response to herpesviruses, these 
viruses have a noteworthy amount of genomic space to encode viral proteins that 
help evade the immune response. For example, HSV-1 counters the immune 
response in the following ways: (i) inhibition of host transcription (ii) degradation 
of host messenger RNAs (mRNAs) and the resultant depletion of short-lived 
cellular proteins by the virion host shutoff (vhs) protein (iii) overcoming the cell-
mediated repression of viral DNA (iv) degradation of cellular proteins needed for 
the immune response by the infected cell polypeptide 0 (ICP0) (v) disruption of 
host mRNA splicing (vi) prevention of apoptosis and autophagy (vii) inhibition of 
antigenic presentation (viii) inhibition of cellular cytotoxicity implemented by the 
immune system (reviewed in [12]).  
 
1.3.2: Intrinsic response to the herpesviruses 
Unlike the intracellular innate response, which requires signaling upon 
viral recognition, the cell’s intrinsic resistance system is setup for an immediate 
response to viral infection. It consists of germline encoded, constitutively 
expressed factors which do not require additional signaling to respond to viral 
infection [39]. In addition to this intrinsic role, a number of these components are 
also induced by IFN. The components of the intrinsic immune system have been 
well established in studies of in vitro tropism for retroviruses- primarily the 
identification of Friend virus susceptibility gene (Fv1) in the restriction of the 
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murine leukemia virus (MLV). Other examples of the intrinsic immune system 
include the APOBEC family of RNA-editing cytidine deaminases. These enzymes 
convert viral cytidine to uridine. Another example is tetherin, which has been 
shown to prevent HIV-1 viral budding, and members of the TRIM superfamily of 
proteins, which differ in their mechanisms of viral inhibition. 
In the context of herpesviruses, the intrinsic immune response consists of 
nuclear domain 10 (ND10) bodies [40]. In addition to being upregulated by IFN, 
these are well-studied intranuclear organelles that confer resistance to the 
herpesviruses. They consist of cellular proteins including TRIM19/ promyelocytic 
leukemia protein (PML), Sp100, hDaxx and α-thalassemia/mental retardation 
syndrome X-linked protein (ATRX) [40]. hDaxx has been shown to repress 
human cytomegalovirus (HCMV) and a replication-defective version of HCMV 
[41].  Both hDaxx and ATRX have been shown to be important in chromatin 
modification and viral gene repression, particularly in HSV-1 and HCMV infection 
[42]. PML will be discussed in further detail later. 
Another intrinsic mechanism of herpesviral inhibition is the silencing of 
viral DNA upon nuclear entry by IFI16. The depletion of IFI16 has been shown to 
promote the replication of an ICP0-null virus [43]. This was due to a reduction in 
the heterochromatin marks and an increase in euchromatin marks associated 
with the viral gene promoters [43]. Much like PML, IFI16 is also upregulated by 
Type I IFN. 
Furthermore, cellular factors involved in the DNA damage repair response 
are also capable of recognizing viral genetic material [44] and localize to sites of 
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incoming viral genomes independently of ND10 components [45]. Although 
components of the Ataxia telangiectasia mutated (ATM)-dependent signaling 
pathway such as ATM and Mre11 are beneficial for lytic replication [46], the 
ubiquitin ligases RNF8 and RNF168 are recruited to incoming viral genomes [47]. 
These proteins in turn recruit 53BP1, a known DNA damage repair protein, in an 
attempt to restore what the cell perceives as “damaged” DNA. Although the effect 
of these proteins on viral replication is yet to be elucidated clearly, these DNA 
damage repair proteins provide a repressive environment for incoming genomes 
[45]. The absence of Ku70, a protein involved in non-homologous end joining, in 
mouse embryonic fibroblasts increases HSV-1 viral replication [48]. 
Much like the viral mediated escape of the innate immune response, the 
herpesviruses encode proteins that confer escape from the intrinsic immune 
response. As an example, the HSV-1 ICP0 counters the host immune response 
by disruption of ND10 bodies, degradation of the components of ND10 bodies 
such as PML and Sp100 [49] and degradation of IFI16 [30]. ICP0 has also been 
shown to counter the DNA damage response by targeting the degradation of the 
DNA repair proteins, RNF8 and RNF168 [47]. Furthermore, ICP0 has been 
demonstrated to sequester the accumulation of a transcription factor important 
for the induction of Type I IFN in the nucleus, or IRF3 [50]. These functions of 
ICP0 are partially attributed to its N-terminal RING domain, which contains E3 
ubiquitin ligase activity.  
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1.3.3: TRIM proteins 
Members of the Tripartite Motif (TRIM) superfamily of proteins are known 
mediators of the intrinsic immune response  (reviewed in [51]). They are found 
throughout the metazoan kingdom with over 60 proteins identified in humans. 
Functionally, they are involved in multiple cellular processes including apoptosis, 
cell differentiation and proliferation, with a number of them involved in anti-viral 
activity. The order and spacing across all TRIM proteins are conserved, in that 
they share a common structure of a RING (‘really interesting new gene’) domain 
followed by one or two B-box domains, a coiled-coil domain and a variable C-
terminal domain.  
The RING domain consists of 40-60 amino acid residues and is capable of 
binding zinc atoms [52]. The RING domain is hypothesized to have E3 ubiquitin 
ligase activity in all TRIM proteins, and this has been validated in TRIM5δ and 
TRIM5α isoforms, TRIM18/MID1, TRIM22, TRIM25, TRIM32 and TRIM35 
(reviewed in [53]). In addition, the RING domain of TRIM19/PML has been shown 
to associate with the SUMO-conjugating enzyme, UBE21, demonstrating its 
potential role in SUMOylation (reviewed in [54]).  
The TRIM proteins also have one or two B-box domains, consisting of two 
CHC3H2 zinc-finger motifs consisting of 40 residues each (reviewed in [53]). They 
have been shown to confer anti-viral specificity and higher-order oligomerization 
in the context of TRIM5 to promote capsid-binding [55],[56]. However, a 
consistent role for the B-box domains across the different TRIM proteins is yet to 
be elucidated (reviewed in [53]).  
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The coiled-coil domain is a secondary protein structure comprised of α-
helices and promotes homo-oligomerization (reviewed in [53]). The presence of 
the coiled-coil domain has been shown to be important for TRIM5’s ability to 
trimerize and function as a restriction factor [57].  
Although the C-terminal domain varies across the different TRIM proteins, 
40% of the 66 TRIM proteins identified have a B30.2/SPRY domain (related to 
the immunoglobulin folds of the butyrophilin protein) ([58], reviewed in [53]). 
Therefore, the domains of the TRIM proteins have been shown to clearly impact 
their anti-viral function. The following sections address the anti-herpesviral role of 
specific TRIM proteins. 
 
1.3.3.1: TRIM19/ PML 
 The initial characterization of TRIM19 was due to a chromosomal 
translocation in acute promyelocytic leukemia patients, resulting in a fusion 
protein with retinoic acid receptor-α (RAR-α) [59] [60,61]. The promyelocytic 
leukemia protein (PML) is involved in a variety of cellular processes including 
apoptosis, cell proliferation, transcriptional and translational regulation, signal 
transduction and the DNA damage response (reviewed in [53], [62]). It is 
hypothesized that the variation in the C-terminal domain of the splice variants 
confers the ability of PML to interact with a variety of different proteins (reviewed 
in [53]). PML is important for the integrity of nuclear domain 10 (ND10) bodies in 
the nucleoplasm [63], in which it is associated with a number of other proteins 
including hDaxx/ATRX and Sp100.  
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PML has both innate and intrinsic functions: It has been shown to regulate 
Type II IFN (IFNγ) signaling [64], and is also upregulated by Type I IFN resulting 
in an increase in the number and size of ND10 bodies. It confers resistance to 
RNA viruses such as HIV-1, vesicular stomatitis virus [65,66] and influenza A 
virus. PML has been shown to inhibit the replication of a number of DNA viruses 
including parvoviruses [67], HCMV and an ICP0-null mutant of HSV-1. 
 
1.3.3.2: TRIM5  
TRIM5 is a well-studied TRIM protein that has been shown to restrict HIV-
1 in Old World monkeys. HIV-1 restriction was previously shown to be a function 
of cross-species restriction factors, Ref 1 and Lv1 ([68-72], reviewed in [67]). The 
TRIM5α isoform in rhesus macaques (rhTRIM5α) has been shown to restrict 
HIV-1 by capsid recognition and accelerated uncoating of the capsid and has 
been shown to be a novel PRR for viral capsid [73,74]. TRIM5 in humans has 
some anti-viral activity against HIV-1. However, this does not show the same 
level of potency as rhTRIM5α [75-77].  
The different domains of TRIM5α have been shown to modulate anti-viral 
activity in the context of HIV-1 restriction [55,57,78-82]. It was also found that a 
single point mutation in the C-terminal SPRY domain of human TRIM5 could 
confer restriction against HIV-1[77]. In addition, expression levels of the human 
TRIM5 and polymorphisms in the TRIM5 gene can also confer resistance against 
HIV-1 [83,84]. Therefore, the literature describing anti-retroviral role of TRIM5 is 
well established.  
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However, the role of TRIM5 in DNA viruses such as herpesviruses was 
only recently elucidated. Rhesus fibroblasts show a 2-log defect in HSV-1 KOS 
replication and a 3-log defect in HSV-2 replication relative to the human cell line, 
HeLa [85]. Upon further investigation, Old World monkey TRIM5α, particularly 
rhTRIM5α, inhibited HSV-1 replication by a few-fold at low multiplicities of 
infection (MOIs), and this is overcome at higher MOIs. This MOI-dependent 
effect on viral restriction is consistent with previous reports of the TRIM5-
mediated restriction of HIV-1 [74]. The TRIM5-mediated effect was at an early 
stage in the viral life cycle prior to immediate-early gene expression. 
Furthermore, the Letvin laboratory demonstrated that haplotypic variation in 
TRIM5 altered the levels of herpesviruses in rhesus macaque cells; rhTRIM5 
genes encoding a two amino acid deletion in the B30.2/SPRY domain 
demonstrated lower permissivity to β- and γ- herpesviruses, particularly rhesus 
CMV and rhesus LCV, than rhesus macaque B-LCLs encoding the TRIM5 with 
wild-type B30.2 domain [86]. These studies established a premise for the study 
of TRIM genes relative to herpesvirus susceptibility.  
 
1.3.3.3: TRIM22 
 TRIM22 or Stimulated Trans-acting factor of 50kDa (Staf50) located on 
chromosome 11p15 was initially identified as a Type I and Type II interferon- 
stimulated gene in a human lymphoblastoid cell line (B-LCL) [87,88]. It was 
further hypothesized to function as a nuclear E3 ubiquitin ligase [89]. Consistent 
with the antiviral role of a number of interferon-stimulated genes, multiple reports 
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have established that TRIM22 is upregulated by IFNα [90-92], PEGylated-IFNα 
[93], IFNβ [92,94], IFNγ [95,96] and upon rubella virus [97] and HIV-1 infection 
[97,98]. In the absence of exogenous IFN, TRIM22 is expressed at high levels in 
immune cells including resting T cells [99]. TRIM22 is consistently repressed in 
activated T cells [99] and was found to be down-regulated in CD4+ lymphocytes 
from a patient with systemic lupus erythematous (SLE), an autoimmune disorder 
[100].  
Besides its additional role as an activator of the non-canonical NF-κB 
pathway [101,102], other reported roles of TRIM22 include its role as an anti-
proliferative and differentiation-associated gene. It has been shown to be a p53 
target gene, to inhibit clonogenic growth of U937 leukemic cells, and to have 
decreased expression during progression of CD34+ human bone marrow 
progenitor cells to late erythroid maturation [103].  
There is evidence for a role for TRIM22 in humans, which include the 
following: (i) Down-regulation of TRIM22 was shown to be associated with 
relapse in patients with Wilms’ tumors or nephroblastomas [104] and increased 
mortality [105]. (ii) TRIM22 expression correlated negatively with plasma viral 
loads in HIV-1 infected patients [106] and correlated positively with CD4+ T cell 
counts in these patients [92]. (iii) TRIM22 has been demonstrated to have 
significant anti-viral activity against human immunodeficiency virus-1 (HIV-1) 
[87,92,94,107,108], encephalomyocarditis virus (ECMV) [109], hepatitis B virus 
(HBV) [110], hepatitis C virus (HCV) [90], and influenza A virus (IAV) [91]. Most 
of the antiviral function of TRIM22 has been attributed to the E3 ubiquitin ligase 
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activity of its pertinent RING domain [89]. It has been shown to mediate the 
ubiquitination of the ECMV 3C protease, which is crucial for the replication of this 
single-stranded RNA virus [109], to target the influenza A virus nucleoprotein for 
degradation [91] and to interrupt HCV replication by ubiquitination of the viral 
NS5A [90].  
The reports on the mechanism of TRIM22-mediated restriction of HIV-1 
are unclear. TRIM22 has been shown to inhibit HIV-1 LTR transcription in a 
RING-domain independent manner [108]. However, mutating the cysteine 
residues at positions 15 and 18 residues in the RING domain of TRIM22 
prevented the trafficking of Gag protein to the plasma membrane, and thus 
abrogated the budding of HIV-1 particles [94]. It has also been shown to inhibit 
the HBV core promoter activity in a RING domain-mediated mechanism. 
However, the role of the RING domain in this study is due to the nuclear 
localization conferred by this domain, rather than its E3 ubiquitin ligase activity 
[110]. 
Interestingly, some viruses potentially hijack the TRIM22’s anti-viral 
properties to prevent super infection upon establishment of latency. TRIM22 was 
shown to be upregulated in cell lines expressing the γ-herpesvirus, KSHV 
latency-associated nuclear antigen (LANA) [111] and EBV latent membrane 
protein 1 (LMP1) [112]. Therefore, TRIM22 as an innate immune gene and other 
functional properties are well established, however its role as a restriction factor 
has not been elucidated. 
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1.3.3.4: Evolutionary history of the TRIM5 and TRIM22 gene neighbors 
The virus-host conflict can be characterized by rapid changes at the host-
virus interface in anti-viral genes such as TRIM5. The ratio of rate of occurrence 
of non-synonymous amino acid substitutions (dN) to the rate of occurrence of 
synonymous amino acid substitutions (dS) or the dN/dS ratio is a means of 
quantifying protein evolution [113]. dS is fixed by random genetic drift and is 
neutral. Therefore, if dN exceeds dS, then the interpretation is that positive 
selection fixes non-synonymous amino acid substitutions faster than neutral 
ones. Conversely, if dN is lower than dS, then purifying selection removes a 
proportion of the non-synonymous amino acid substitutions and refers to high 
conservation.  
The anti-viral TRIM5 gene sits in a gene cluster with TRIM6, TRIM34 and 
TRIM22 at position 11p15.4.  Evolutionary analysis of the primate TRIM5 gene of 
17 primate genomes spanning 33 million years of evolution demonstrated that it 
was positively selected for, predating the origin of primate lentiviruses, which 
have been hypothesized to originate <1 million years ago [114,115]. The authors 
suggested that the episodic positive selection of the TRIM5 gene in primates is 
influenced by interaction with endogenous retroviruses and retrotransposition 
events. This positive selection was concentrated on residues in the C-terminal 
SPRY domain, a region known to be important for lentiviral interaction [114].  
Further investigation of the dN/dS parameter of the TRIM5 and TRIM22 
gene neighbors in human, rhesus macaque and chimpanzee genomes showed 
that TRIM22, much like TRIM5, is also positively selected for in primates [116]. 
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Further analysis of the TRIM22 genes in 21 primate genomes spanning 33 
million years of primate divergence provided strong support for the positive 
selection of TRIM22 in the hominoid and Old World monkey clades, suggesting 
that it has been positively selected since 23 million years ago [116].  
Interestingly, the TRIM5 and TRIM22 gene neighbors underwent 
discordant evolution with either one or the other being positively selected for in 
the hominoid and Old World monkey species investigated [116]. In addition, the 
cow genome includes an expanded cluster of TRIM5 genes but no TRIM22 gene, 
while the dog genome encodes TRIM22 but does not encode TRIM5 [116]. 
These findings all suggested that TRIM22, much like TRIM5, has the 
evolutionary trademarks of an intrinsic immune gene.  
Given the prior evidence that TRIM5 in rhesus macaques restricts HSV-1, 
and haplotypic variability in the rhTRIM5 gene associates with lower rhCMV and 
rhLCV viral loads, we wanted to address whether TRIM22 variability affects 
human susceptibility to herpesviruses. The established anti-viral properties of 
TRIM22 in many hosts support our hypothesis that TRIM22 may also affect viral 
infection in humans. Therefore, we investigated the potential restrictive ability of 
TRIM22 in HSV-1, HCMV and EBV.   
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Abstract 
Intrinsic resistance is a crucial line of defense against virus infections and 
members of the Tripartite Motif (TRIM) family of proteins are major players in this 
system, particularly TRIM19/PML in ND10 bodies. Previous reports on the anti-
viral function of another TRIM protein, TRIM22, emphasized its innate immune 
role as a Type I and Type II interferon-stimulated gene against RNA viruses. This 
study shows that TRIM22 has an additional intrinsic role against DNA viruses. 
Here, we report that TRIM22 is a novel restriction factor of HSV-1 and limits 
ICP0-null virus replication by modulating histone occupancy and heterochromatin 
in shutting off immediate-early (IE) viral gene expression. The corresponding 
wild-type equivalent of the virus evades the TRIM22-specific restriction by a 
mechanism independent of ICP0-mediated degradation. We also demonstrate 
that TRIM22 inhibits other DNA viruses, including representative members of the 
β- and γ- herpesviruses. Collectively, these results strengthen the case for 
intrinsic resistance to foreign DNA in the nucleus and argue that TRIM22 is a 
hitherto, unknown component of this system.  
 
 
 
 
 
 
 
	   	   	   	   	   	  
 26 
Introduction 
The intrinsic immune system consists of constitutively expressed, germline 
encoded restriction factors that provide an immediate anti-viral response in host 
cells [39]. This system includes members of the Tripartite Ring Interaction Motif 
(TRIM) proteins, which have important roles in viral inhibition in addition to being 
involved in diverse cellular processes [102,103,117-119]. In the context of the 
nuclear-replicating DNA virus family, the herpesviruses, nuclear domain 10 
(ND10) bodies are well-established sub-organelles that confer resistance to the 
ubiquitous herpesviruses [120]. They consist of cellular proteins including 
TRIM19/promyelocytic leukemia protein (PML), Sp100, hDaxx and α-
thalassemia/mental retardation syndrome X-linked protein (ATRX) [121]. PML, 
Sp100 and hDaxx depletion increases the infectivity of an ICP0-null herpes 
simplex virus-1 (HSV-1) virus, and Sp100 has been implicated in the repression 
of HSV-1 gene expression [122]. ATRX and hDaxx depleted cells also 
demonstrate increased plaque formation and gene expression of an ICP0-null 
HSV-1 virus [42]. HDaxx has been shown to repress human cytomegalovirus 
(HCMV) and a replication-defective version of HCMV [123].  Both hDaxx and 
ATRX have been shown to be important in chromatin modification and viral gene 
repression, particularly in HCMV infection [124].  
To counteract the restriction exerted by the various known intrinsic 
immune factors, the herpesviruses encode a number of proteins that allow for 
virus propagation, even in relatively hostile conditions implemented by the host 
interferon (IFN) responses [12]. This includes the infected cell polypeptide 0 
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(ICP0), which degrades components of the intrinsic immune system, such as γ-
interferon-inducible protein 16 (IFI16) and components of the nuclear ND10 
bodies [12,30,125-127]. ICP0 also sequesters interferon regulatory factor 3 
(IRF3) from the IFNB gene promoter, thus preventing the expression of this Type 
I IFN [12,128,129]. In addition, ICP0 counters host chromatin silencing 
mechanisms, allowing for the de-repression of early (E) genes [130,131]. As a 
result, ICP0-null viruses demonstrate a 10 to 100-fold replication defect relative 
to the wild-type viruses in primary cells [132,133]. Although depletion of known 
restriction factors of HSV-1 such as PML and IFI16 rescue a significant 
proportion of the defect in ICP0-null virus replication, we hypothesized that there 
were other factors that could contribute to this restriction. 
One such candidate was the human TRIM22 protein, which is the paralog 
of the prototypical TRIM protein- rhesus macaque TRIM5α (rhTRIM5α) [134]. 
RhTRIM5α was reported to inhibit lentiviruses, and also HSV-1 [135]. Sequence 
analyses of rhTRIM5 and human TRIM22 genes from 27 primate genomes 
demonstrated that both TRIM22 and TRIM5 underwent positive selection such 
that either TRIM5 or TRIM22 was selectively modified within a given species, 
arguing for selective evolutionary pressure exerted by species-specific 
pathogens [116]. These studies suggested that TRIM22 in humans has a similar 
functional anti-viral response against viruses, similar to rhTRIM5α. In fact, 
TRIM22 is an interferon (IFN)-inducible protein that has antiviral activity against a 
range of viruses, particularly RNA viruses [91,94,108,109] and a DNA virus, the 
hepatitis B virus (HBV) [110]. In addition, TRIM22 expression has also been 
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correlated with the induction of an anti-viral state upon establishment of latency 
in members of the γ-herpesvirus family such as Kaposi’s sarcoma herpes virus 
(KSHV) (23) and the Epstein-Barr virus (EBV) [112,136]. Furthermore, TRIM22 
was previously reported to be upregulated in the first 24h of HCMV infection in 
HFFs [137]. However, the role of TRIM22 as an intrinsic immune factor in HSV-1 
infection has not been investigated.  
Here, we report that TRIM22 limits ICP0-null virus replication by 
modulating histone occupancy and heterochromatin in shutting off immediate-
early (IE) viral gene expression. The ICP0-rescued virus partially evades the 
TRIM22-specific restriction by a mechanism independent of ICP0-mediated 
degradation. In this study, we report that TRIM22 rescues part of the replication 
defect of the ICP0-null virus. In addition, we also find that the restrictive effect of 
TRIM22 is not limited to HSV-1 but is also seen with other viruses that replicate 
in the nucleus, such as HCMV and EBV. These results strengthen the case for 
TRIM22 as a novel component of the intrinsic immune response to the 
herpesviruses.  
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Materials and Methods 
Cell Culture and Viruses. HFFs (Catalog number: CRL-1634), U2OS, HeLa and 
HEK293 were obtained from the American Type Culture Collection. HFFs were 
cultured as described previously [43]. U2OS and HeLa cells were grown in 
DMEM supplemented with 5% (vol/vol) heat-inactivated fetal bovine serum (FBS) 
and 5% (vol/vol) heat-inactivated bovine calf serum (BCS). HEK293 cells stably 
transduced with CD21 and HLA-II [138] were obtained from the Fingeroth 
laboratory and cultured as previously described in selection media. The ICP0-null 
(7134) and rescued 7134R viruses were grown and titrated on U2OS cells in 
parallel [139]. Donald Coen provided HCMV AD169 and it was propagated as 
described previously [140]. 
 
Virus Infections. HSV was diluted in PBS solution containing 0.1% glucose and 
1% heat-inactivated BCS. Cells were infected at the stated MOI for 1h at 37°C, 
washed twice with PBS solution, and overlaid with DMEM containing 1% heat-
inactivated BCS. Infected cells were incubated at 37°C for the indicated length of 
time. HCMV AD169 stocks were diluted in DMEM containing 10% FBS and cells 
were infected at the stated MOI for 1h at 37°C, washed twice with PBS solution, 
and overlaid with DMEM containing 10% FBS. Infected cells were incubated at 
37°C for the indicated length of time. EBV-GFP stocks were prepared from a cell 
line kindly donated by Wolfgang Hammerschmidt as previously described [141], 
and the virus was diluted in DMEM containing 10% FBS and cells were infected 
for 5 days at 37°C.  
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siRNA Transfections. Double-stranded TRIM22-specific, and non-target control 
siRNAs were purchased from Dharmacon. The pooled siRNAs were transfected 
into HFFs using the DharmaFECT 2 transfection reagent (Dharmacon) at a final 
concentration of 50nM according to manufacturer’s instructions. Cells were split 
into two separate wells at 72h post-transfection and transfected again as 
described above. Cells were infected after the second round of 72h post-
transfection. The siRNA was replaced 24hpt with incubation media in both 
rounds of transfection, and cells were assayed for TRIM22 or 18S levels by RT-
qPCR and immunoblot at 72hpt after the second round of transfection. 
 
Plasmids and DNA Transfection. The TRIM22 cDNA was extracted from B 
lymphoblastoid cell lines from the Hap Map project and cloned into the pLPCX 
vector backbone (Clontech). The plasmids encoding the TRIM22 constructs 
lacking the different domains were a kind gift from Dr. Valerie Lin [142]. HeLa 
cells were plated and transfected with the Effectene reagent according to the 
manufacturer’s instructions. Transfected cells were either treated with PBS or 
hIFNα-2a at 24 hours post transfection (hpt) and infected 24h post-treatment. 
 
Cellular RNA Analysis by qPCR. Total RNA was extracted using the Qiagen 
RNeasy Kit and DNase treated using the DNA-free kit (Ambion). Equal amounts 
of RNAs were reverse-transcribed and quantified by real-time qPCR by using the 
Fast Power SYBR Green PCR master mix and Step One PCR sequence 
detection system (Applied Biosystems). qPCR reactions were carried out in 
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triplicate, and relative copy numbers were determined by comparison with 
standard curves. Mock reverse-transcribed samples were included as negative 
controls. Transcript levels were normalized to 18S rRNA levels and made relative 
to mock-infected samples.  
 
Nuclear DNA Analysis. Nuclei from 7134 or 7134R-infected cells were isolated 
using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo-Scientific), 
and DNA was harvested from these nuclei by using a DNeasy blood and tissue 
column kit. Viral DNA levels were determined by RT-qPCR. 
 
Western Blots. Cells were lysed in NuPAGE LDS Sample Buffer, and proteins 
were resolved on NuPAGE 4% to 12% Bis-Tris gels (Invitrogen). Proteins were 
transferred overnight to nitrocellulose membranes and blocked with 5% milk in 
PBS solution containing 0.1% Tween-20 (PBS-T). Membranes were probed with 
primary antibody at 4°C overnight, washed with PBS-T and incubated in 
secondary antibody for 1h at room temperature. Western blots were developed 
using the Super Signal Pico or Forte Chemiluminescence substrate.  
 
Indirect Immunofluorescence. HeLa cells grown on coverslips were transfected 
with the TRIM22 mutants and fixed and permeabilized as previously described. 
Briefly, cells were fixed with 3.7% formaldehyde for 15 minutes on ice and 
permeabilized with 0.2% Triton-X100 for 15 minutes at room temperature [142]. 
Cells were blocked overnight with DMEM-02 and incubated with anti-FLAG M2 
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mouse (Sigma-Aldrich) for 1h at room temperature, washed twice with PBST and 
once with PBS. Fluor 488-conjugated secondary antibodies (Invitrogen) were 
incubated with cells for 1h at 25°C in dark. The coverslips were washed as 
described earlier and DAPI at a dilution of 1:1000 was added during the second 
PBST wash. Coverslips were mounted in ProLong Gold antifade reagent 
(Invitrogen). Images were acquired by using a confocal microscope (Olympus) 
with a 60x objective and in a single Z plane. Images were arranged in figures by 
using Adobe Photoshop CS4 (Adobe Systems).  
 
Flow Cytometry. HEK293 cells infected with EBV-GFP were trypsinized, 
collected by centrifugation and resuspended in solution containing Aqua-Amine. 
Cells were washed twice in PBS and resuspended in fixing solution for 15 
minutes at 4°C. Cells were counted using a flow cytometer and live cells were 
gated for using an Aqua-Amine negative gate after exclusion of doublets on 
forward and side scatter axes. GFP+ gate was defined on mock-infected cells. 
Data analysis was performed using FlowJo (version 8) software and graphs were 
constructed by using Graph Pad Prism software.  
 
Chromatin Immunoprecipitation. HFFs were transfected with siRNAs as 
described earlier and after the first round of transfection, 5.5x105 cells were 
plated in 60mm dishes and transfected for the second round of transfection. Cells 
were infected at 72hpt, and the ChIP protocol was conducted as previously 
described [143]. Prior to immunoprecipitation, 10ul of the sample is reverse 
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cross-linked as previously described and DNA is extracted and gel 
electrophoresis is conducted on a 1% gel to ensure DNA fragments are ~500bp 
in length. Immunocomplexes were immunoprecipitated overnight at 4°C with 
2.5µg of anti-histone H3 IgG (Abcam) and anti-histone H3K9me3 (Active Motif).  
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Results 
Depletion of TRIM22 rescues ICP0-null HSV replication in normal human 
foreskin fibroblasts 
To determine the role of TRIM22 as an interferon-stimulated gene (ISG) in 
HSV-1 replication, we measured virus yields of the HSV-1 7134 ICP0-null virus 
or the corresponding 7134R rescued virus in TRIM22-depleted fibroblasts under 
conditions of Type I IFN pre-treatment. We transfected primary human foreskin 
fibroblasts (HFFs) with pooled siRNAs specific for TRIM22 or non-targeting 
siRNAs twice to deplete TRIM22 transcripts. To upregulate TRIM22, we treated 
the transfected cells with either IFNα (1000U/ml) or a PBS control 24h prior to 
infection with the 7134 or 7134R viruses (MOI=5) and measured virus yields at 
24hpi. Upon comparison of TRIM22 transcripts in control-depleted and TRIM22-
depleted fibroblasts, the knockdown efficiency was approximately 84% in the 
PBS pre-treated cells and 87% in the IFNα pre-treated cells (Figure 2.1A). The 
levels of TRIM22 protein were not detectable by western blotting in TRIM22-
depleted HFFs, even in the IFNα pre-treated HFFs (Figure 2.1B). We observed 
an increase in 7134 virus yields in TRIM22-depleted HFFs relative to control-
depleted HFFs under conditions of PBS pre-treatment (Figure 2.1C). IFNα pre-
treatment reduced 7134 virus yields by approximately 10-fold relative to PBS pre-
treatment in HFFs, and TRIM22 depletion did not rescue IFNα-mediated 
inhibition of 7134 (Figure 2.1C). The magnitude of the TRIM22-mediated 
inhibition on the 7134 virus was possibly due to a synergistic effect of all the 
individual TRIM22-specific siRNAs used (Figure 2.2A). Interestingly, at a low MOI 
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(0.1 pfu/cell), TRIM22 depletion rescued a substantial portion of the IFNα- and 
IFNγ-mediated inhibition of the 7134 virus replication (Figure 2.3). These results 
argued that TRIM22 inhibits the replication of the ICP0-null virus and mediates 
some of the anti-viral effect of IFNα at a low MOI.  
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Figure 2.1: TRIM22 depletion increases HSV-1 viral yields. HFFs were 
transfected with siRNA pools specific for TRIM22 or non-targeting siRNAs. 
Transfected HFFs were treated with PBS or hIFNα-2a at 1000U/ml for 24h and 
then were infected with HSV-1 ICP0-null (7134) or a rescued virus (7134R) at an 
MOI of 5. TRIM22 transcript levels were measured by RT-qPCR with primers 
specific for TRIM22 and 18S (n=3) (A) and protein levels were determined by 
immunoblotting for TRIM22 and GAPDH (B) at time of infection. Virus yields were 
measured 24hpi by plaque assays on U2OS cells (n=3) (C). Error bars represent 
standard errors of the means (*P<0.05, Student’s t-test). 
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Figure 2.1 (Continued) 
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Figure 2.2: TRIM22 depletion by individual siRNAs increases viral yields.  
HFFs were transfected with individual siRNAs specific for TRIM22 (si T22#6, si 
T22#7, si T22#8 or si T22#9) or non-targeting siRNAs (si NT#2) and infected with 
HSV-1 ICP0-null (7134) or a rescued virus (7134R) at an MOI of 5. Virus yields 
were measured 24hpi by plaque assays on U2OS cells (n=3) (A). Virus yields 
were plotted against knockdown efficiencies for individual siRNAs (B). TRIM22 
knockdown efficiency was measured by RT-qPCR (n=1) (C) and protein levels 
were determined by immunoblotting (D) at time of infection.  
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Figure 2.2 (Continued) 
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Figure 2.3: TRIM22 depletion increases virus yields in IFN pre-treated cells.  
HFFs were transfected with siRNA pools specific for TRIM22 or non-targeting 
siRNAs and were treated with PBS or hIFNα-2a (n=3) or hIFNγ (n=2) at 
1000U/ml for 24h. Cells were then infected with HSV-1 ICP0-null (7134) or a 
rescued virus (7134R) at an MOI of 0.1 and virus yields were measured 48hpi by 
plaque assays on U2OS cells (A). TRIM22 knockdown efficiency was measured 
by RT-qPCR (n=2) (B). 
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Depletion of TRIM22 enhances HSV-1 IE viral gene expression 
After HSV-1 enters the nucleus, the replication cycle initiates with transcription of 
immediate-early (IE) genes followed by early (E) gene transcription [144] . To 
characterize the TRIM22-mediated block in HSV-1 replication, we measured the 
transcript levels of IE (ICP27) and E (ICP8) viral genes in TRIM22-depleted 
fibroblasts relative to control-depleted fibroblasts upon 7134 and 7134R virus 
infection. TRIM22 depletion consistently reduced TRIM22 transcripts relative to 
non-targeting siRNA transfected HFFs at 8hpi (Figure 2.4A). TRIM22 depletion 
increased the expression of ICP27 and ICP8 transcript levels by approximately 3-
fold upon infection with the 7134 virus in PBS pre-treated fibroblasts at 8hpi 
(Figure 2.4B, C). There was also a marked increase in expression of the IE ICP4 
protein, and in the E ICP8 protein levels (Figure 2.4D). We also observed a 
marked increase in TRIM22 protein levels in 7134 infection, consistent with 
TRIM22’s role as an ISG (Figure 2.4D). It must be noted that the TRIM22 levels 
that appear lower in 7134R infection are comparable to levels observed in mock 
infection (Figure 2.5). These results suggest that the TRIM22-mediated inhibition 
of the HSV-1 ICP0-null virus is either at or prior to the level of IE gene 
transcription. The increase in viral IE gene expression was not due to altered 
nuclear entry of the virus, as TRIM22 depletion did not alter the number of 7134 
virus genomes associated with the nuclear fractions at 2hpi (Figure 2.4E).  
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Figure 2.4: TRIM22 depletion increases viral IE, E and L gene expression. 
Control siRNA or TRIM22 siRNA transfected HFFs treated with PBS or hIFNα-2a 
at 1000U/ml for 24h were infected with HSV-1 ICP0-null (7134) or a rescued 
virus (7134R) at an MOI of 5. Total cell-associated RNA was harvested at 8hpi 
and prepared for RT-qPCR. TRIM22 transcripts (A), ICP27 transcripts (B) and 
ICP8 transcripts (C) were measured and normalized to 18S rRNA (n=3). Whole 
cell lysates were collected at 24hpi and immunoblotted for ICP4, ICP8, TRIM22 
and GAPDH protein levels (D). DNA was extracted from the nuclear fractions of 
infected cells at 2hpi and prepared for qPCR (n=3) (E) (left panel). The western 
blot shows the efficiency of fractionation qualitatively (E) (right panel). Relative 
viral DNA levels were determined by normalizing ICP8 vDNA levels to cellular 
GAPDH levels. Error bars represent standard errors of the means (*P<0.05, 
Student’s t-test). 
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Figure 2.4 (Continued) 
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Figure 2.5: TRIM22 is not degraded by ICP0. Control siRNA (NT si) or TRIM22 
siRNA (T22 si) transfected HFFs were either mock-infected or infected with HSV-
1 ICP0-null (7134) or a rescued virus (7134R) at an MOI of 5. Whole cell lysates 
were collected at 8hpi and immunoblotted for ICP0, IFI16, TRIM22 and GAPDH 
protein levels.  
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Depletion of TRIM22 increases HSV-1 viral DNA replication and L gene 
expression 
To determine whether the defect in IE and E gene expression was evident 
at the downstream stage of viral DNA (vDNA) synthesis, we measured vDNA 
levels in TRIM22-depleted and control-depleted HFFs. TRIM22 depletion 
increased vDNA synthesis of the 7134 virus in both PBS pre-treated and IFNα 
pre-treated HFFs, consistent with the increase in IE and E viral gene expression 
(Figure 2.6A). In addition, the TRIM22-mediated effect on vDNA synthesis was 
consistent with the increase in the expression levels of transcripts encoding 
components of the viral replication machinery: UL5 (~3 fold), UL8 (~4 fold), UL9 
(~4 fold), UL30 (~3 fold), UL42 (~6 fold) and UL52 (~4 fold) (Figure 2.7). The 
defects in viral gene expression and vDNA replication were corroborated by L 
viral gene expression as TRIM22 depletion increases gC transcript levels and 
protein levels relative to control-depleted HFFs (Figure 2.8A and B). These 
results argued that the TRIM22-mediated defect in IE gene expression results in 
an inhibition of downstream viral processes, including viral replication. 
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Figure 2.6: TRIM22 depletion increases viral DNA replication. HFFs 
transfected with siRNA pools specific for TRIM22 (red lines) or non-targeting 
siRNAs (black lines) and treated with PBS (solid lines) or hIFNα-2a (dashed 
lines) at 1000U/ml for 24h were infected with HSV-1 ICP0-null (7134) (top 
panels) or a rescued virus (7134R) (bottom panels) at an MOI of 5. Total cell-
associated DNA was harvested at 2hpi (n=4), 8hpi (n=3) and 24hpi (n=2) and 
prepared for qPCR (A). Relative viral DNA levels were determined by normalizing 
ICP8 vDNA levels to cellular GAPDH levels. 
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Figure 2.6 (Continued) 
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Figure 2.7: TRIM22 depletion increases expression of components of viral 
replication machinery. TRIM22-depleted or control-depleted HFFs were treated 
with PBS or hIFNα-2a at 1000U/ml for 24h and infected with HSV-1 ICP0-null 
(7134) or a rescued virus (7134R) at an MOI of 5. Total cell-associated RNA was 
harvested 8hpi and transcript levels of UL5 (A), UL8 (B), UL9 (C), UL30 (D), 
UL42 (E) and UL52 (F) were measured by RT-qPCR. The transcript levels were 
normalized to 18S rRNA (n=3). Fold differences due to TRIM22 depletion are 
shown above corresponding bars. 
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Figure 2.7 (Continued) 
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Figure 2.8: TRIM22 depletion increases L gene expression. HFFs were 
transfected with siRNA pools specific for TRIM22 or non-targeting siRNAs and 
were treated with PBS or hIFNα-2a at 1000U/ml for 24h and infected with HSV-1 
ICP0-null (7134) or a rescued virus (7134R) at an MOI of 5. Total cell-associated 
RNA was harvested at 4hpi (left panel) and 8hpi (right panel) and prepared for 
RT-qPCR. gC transcripts were measured and normalized to 18S rRNA levels 
(n=2) (A). Whole cell lysates were collected at 4hpi and 8hpi and the 
representative western blot shows gC, TRIM22 and GAPDH protein levels. 
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Figure 2.8 (Continued) 
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Over-expression of TRIM22 reduces ICP0-null and ICP0-rescued virus 
replication 
To test whether TRIM22 was sufficient for the inhibition of the 7134 virus, 
we measured virus yields in HeLa cells transfected with either a TRIM22-
encoding plasmid or a control plasmid (pLPCX). We chose HeLa cells because 
they express TRIM22 at low levels relative to the other cell types that we 
screened and HeLa cells were also used as cell lines of choice in prior 
publications of TRIM22 (Figure 2.9, [142]). We observed high levels of TRIM22 
transcripts and protein upon transfection relative to the empty vector (Figure 
2.10A, B). TRIM22 over-expression in HeLa cells reduced both 7134 and 7134R 
virus yields by approximately 10-fold at an MOI of 0.1 pfu/cell relative to pLPCX 
transfection (Figure 2.10C). The magnitude of this difference was negligible at a 
high MOI of 5 in HeLa cells, despite high levels of expression of the TRIM22 
transcripts and protein upon transfection (Results not shown). This MOI-
dependent effect was consistent with previous studies using exogenous 
expression systems of the rhesus paralog, rhTRIM5α, where the TRIM5-
mediated inhibition of HSV-1 is overcome at higher MOIs [135]. In addition, the 
exogenous expression of TRIM22 protein reduced IE (ICP4) protein levels 
(Figure 2.10C), complementing the results observed in RNA interference studies. 
Therefore, these results argued that TRIM22 is sufficient in the context of HSV-1 
inhibition and that this block in replication is at the stage of IE viral gene 
expression. 
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Figure 2.9: TRIM22 expression in different cell types. RNA was prepared for 
RT-qPCR from transformed cells (293, 293T, HeLa, U2OS) or primary cells 
(HFFs, normal oral keratinocytes) or HeLa cells transfected with the empty 
vector, pLPCX (P) or the vector encoding full-length TRIM22 (T). The levels of 
TRIM22 transcripts were measured and normalized to 18S rRNA (n=3). 
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Figure 2.10: Overexpression of TRIM22 reduces HSV-1 replication. HeLa 
cells transfected with an empty vector control (pLPCX) or a vector with a TRIM22 
insert (TRIM22) were treated with PBS or hIFNα-2a at 1000U/ml for 24h. 
Transfected cells were infected with ICP0-null (7134) or rescued virus (7134R) at 
an MOI of 0.1. Total cell-associated RNA was harvested at time of infection and 
prepared for RT-qPCR. TRIM22 transcripts were normalized to 18S rRNA (A). 
Virus yields were determined 48hpi with plaque assays on U2OS cells (B) (n=4). 
Representative western blot showing total cell lysates probed for ICP4, TRIM22 
and GAPDH protein levels at 24hpi (C) (*P<0.05, Student’s t-test).  
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Figure 2.10 (Continued) 
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Inhibition of HSV-1 by TRIM22 is dependent on its nuclear localization  
The domains of TRIM22 have different functions in the cell. The N-
terminal RING domain has E3 ubiquitin ligase activity [89] and was reported to 
mediate anti-viral activity against hepatitis B virus (HBV) [145], 
encephalomyocarditis virus (ECMV) [109] and influenza A virus (IAV) [91]. The 
C-terminal B30.2/SPRY domain and the bipartite nuclear localization signal 
(NLS) are necessary for the nuclear localization of TRIM22 [142]. Therefore, we 
investigated whether these domains were necessary for TRIM22-mediated 
inhibition of HSV-1. To define the expression levels and localization properties of 
these TRIM22 mutants, we transfected HeLa cells with the following plasmids: 
empty vector or FLAG-tagged constructs encoding full-length TRIM22 (TRIM22), 
a nuclear localization signal deleted TRIM22 (TRIM22-ΔNLS), a SPRY-domain 
deleted TRIM22 (TRIM22-ΔSPRY), a RING-domain deleted TRIM22 (TRIM22-
ΔRING) and an E3 ubiquitin-ligase inactive form of TRIM22 (TRIM22-
C15A/C18A) [142]. The transfected constructs localized to sites in the cell as 
described previously (Figure 2.11A, [142]). The full-length TRIM22 formed 
nuclear punctae, as did the TRIM22-ΔRING protein and the TRIM22-C15A/C18A 
proteins to a smaller extent (Figure 2.11A). The TRIM22-ΔNLS localized to both 
the nucleus and cytoplasm, whereas the TRIM22-ΔSPRY localized to the 
cytoplasm (Figure 2.11A). The encoded proteins were expressed at the expected 
sizes and at comparable levels, except for TRIM22-C15A/C18A, which showed 
drastically lower protein levels consistent with the lower expression seen in 
immunofluorescence (Figure 2.11B).  
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Figure 2.11: TRIM22 nuclear localization mediates HSV-1 inhibition. 
Subcellular localization in HeLa cells transfected with an empty vector control 
(Empty vector) or vectors encoding full-length TRIM22 (TRIM22), the nuclear 
localization signal deleted mutant of TRIM22 (TRIM22-ΔNLS), the SPRY-domain 
deleted TRIM22 (TRIM22-ΔB30.2/SPRY), the RING-domain deleted TRIM22 
(TRIM22-ΔRING), the E3 ubiquitin-ligase inactive form of TRIM22 (TRIM22-
C15A, C18A) was determined by staining for anti-FLAG and nuclei were counter-
stained with DAPI (A). Transfected cells were lysed and probed for the FLAG-tag 
and GAPDH as a loading control (B). Transfected cells were infected at 0.1 MOI 
with 7134 or 7134R viruses and virus yields were measured 48hpi by plaque 
assays on U2OS cells (n=6) (C). (*P<0.05, ***P<0.001 Two-way ANOVA with 
Bonferroni tests). 
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Figure 2.11 (Continued) 
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We infected the transfected cells with the 7134 and 7134R viruses at 0.1 
MOI and measured virus yields 48hpi. Transfection with TRIM22 or any of the 
other TRIM22 mutants reduced viral yields of the ICP0-null virus by 
approximately 2-fold relative to the empty vector transfection (Figure 2.11C). 
Transfection with TRIM22 significantly reduced 7134R viral yields (Figure 2.11C). 
Interestingly, transfection with TRIM22-ΔNLS showed comparable viral yields to 
transfection with TRIM22 (Figure 2.11C). This is consistent with the partial 
localization of TRIM22-ΔNLS (Figure 2.11B). However, transfection with the 
SPRY domain deleted mutant (TRIM22-ΔSPRY) reduced the TRIM22-mediated 
inhibition to levels similar to those observed upon transfection with the empty 
vector (Figure 2.11C). This is consistent with the cytoplasmic localization of the 
TRIM22-ΔSPRY mutant (Figure 2.11B). Interestingly, transfection with the RING 
domain deletion mutant and the inactive RING mutant (TRIM22-ΔRING and 
TRIM22-C15A/C18A) showed an intermediate phenotype in reducing the 
TRIM22-mediated inhibition of the 7134R virus (Figure 2.11C), despite the 
nuclear localization of these proteins (Figure 2.11B).  
These results argued that the nuclear localization conferred by the SPRY 
domain of TRIM22 is important for the restriction of HSV-1, as is the E3 ubiquitin 
ligase activity conferred by the RING domain to a smaller extent. The NLS 
mutant does not seem to be as functionally effective in excluding TRIM22 from 
the nucleus, and therefore is still capable of HSV-1 restriction. 
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TRIM22 depletion reduces total histone occupancy and facultative 
heterochromatin on IE viral gene promoters 
The host cell silences viral DNA upon nuclear entry by incorporating free 
DNA into chromatin [146-148]. In addition, histones are post-translationally 
modified, thereby leading to heterochromatin formation (H3K9me3 and 
H3K27me3) or euchromatin formation (H3K9Ac and H3K4me3). To determine 
whether TRIM22 depletion increases viral gene expression due to reduced 
histone occupancy or by modifying histones on viral gene promoters, we 
conducted chromatin immunoprecipitation assays on total histone H3, the 
heterochromatin mark, H3K9me3, the facultative heterochromatin mark, 
H3K27me3, and the euchromatin marks H3K4me3 and H3K9Ac on the viral IE 
ICP4 and ICP27 gene promoters in TRIM22-depleted fibroblasts relative to 
control-depleted fibroblasts. TRIM22 depletion significantly reduced the total 
histone H3 occupancy on the viral IE gene promoters (Figure 2.12A). In addition, 
TRIM22 depletion reduced the density of H3K9me3 and H3K27me3 
immunoprecipitated on the ICP27 and ICP4 promoters in the 7134 virus infection, 
indicating that the viral DNA is not silenced to the same extent in TRIM22-
depleted fibroblasts (Figure 2.12B and C). The reduced facultative 
heterochromatin on vDNA in TRIM22-depleted fibroblasts was consistent with the 
increase in viral IE gene expression observed in Figure 2.4. 
Although TRIM22 depletion did not significantly change the levels of 
euchromatin marks on ICP27 and ICP4 promoters, a greater proportion of ICP27 
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transcripts were detected with H3K9Ac immunoprecipitation (Figure 2.12D and 
E). These results argued that the absence of TRIM22 prevents compaction of 
viral DNA, reduces heterochromatin and facultative heterochromatin, providing a 
mechanism by which TRIM22 inhibits HSV-1 gene expression and replication. 
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Figure 2.12: TRIM22 depletion reduces total H3 and facultative 
heterochromatin association with viral DNA. Control- or TRIM22-siRNA 
transfected HFFs were infected with HSV-1 ICP0-null (7134) or HSV-1 ICP0-
rescued (7134R) viruses at a MOI of 5. ChIP was conducted on cell extracts 
prepared at 6hpi with antibodies specific for histone H3 (n=6) (A), the 
heterochromatin mark H3K9me3 (n=3) (B), the facultative heterochromatin mark 
H327me3 (n=3) (C), the euchromatin marks H3K9Ac (n=3) (D) and H3K4me3 
(n=3) (E). Immunoprecipitated ICP27 (left panels) and ICP4 right panels) 
promoter sequences were measured by qPCR and viral DNA sequences were 
normalized to immunoprecipitated GAPDH DNA. (*P<0.05, **P<0.01 Student’s t-
test). 
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TRIM22 restricts a β- and a γ-herpesvirus 
Previous reports demonstrated that TRIM22 inhibits a diverse range of 
viruses, including RNA viruses such as HIV-1, EMCV, IAV, and a DNA virus, 
HBV [91,94,108,109]. To test whether TRIM22 was capable of inhibiting other 
herpesviruses besides the canonical α-herpesvirus, HSV-1, we investigated 
whether TRIM22 could inhibit a γ-herpesvirus, Epstein-Barr virus (EBV). In fact, 
the latent membrane protein 1 (LMP1) of EBV establishes an anti-viral cellular 
state by up-regulating TRIM22 among other ISGs to prevent super-infection 
[112]. Therefore, we measured the efficiency of EBV-GFP infection in HEK293 
cells expressing the EBV receptors, CD21 and HLA-II, after stable transfection 
with the empty vector (pLPCX) or full-length TRIM22 (TRIM22). Transformation 
of cells with TRIM22 did not significantly alter the expression of CD21 (Figure 
2.13A) or HLA-II (Figure 2.13B) or the percentage of CD21+ HLA-II+ transduced 
HEK293 cells (Figure 2.13C). TRIM22 expression was confirmed by 
immunoblotting in multiple single-cell clones and compared to endogenous levels 
in cells expressing the empty control pLPCX vector (Figure 2.13D). We observed 
significantly fewer EBV-GFP-positive cells in TRIM22-transfected cells relative to 
pLPCX-transfected cells (Figure 2.13E). These results argued that TRIM22 
inhibits the efficiency of EBV-GFP infection. We also measured HCMV viral 
yields at 72hpi in control-depleted versus TRIM22-depleted HFFs. TRIM22 
depletion significantly increased HCMV viral yields by approximately 2.5-fold 
relative to control-depletion (P = 0.0364) (Figure 2.13F). These results argued 
that TRIM22 inhibits HCMV replication also. Interestingly, TRIM22 transfection 
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did not inhibit the replication of an RNA virus that replicates in the cytoplasm, 
VSV-GFP (Figure 2.13G). In conclusion, the TRIM22-mediated viral inhibition is 
not limited to the α-herpesviruses and TRIM22 potentially inhibits other DNA 
viruses that replicate in the nucleus, including the β- and γ- herpesviruses.  
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Figure 2.13: TRIM22 inhibits a β- and a γ- herpesvirus. HEK293 cells stably 
transfected with CD21 and HLA-II, and either the empty vector or the full-length 
TRIM22 vector were infected with EBV-GFP at 17 Green Raji Units (GRU). CD21 
MFI (A) and HLA-II MFI (B) and percentage of live cells as determined by 
counter-staining with aqua-amine that are CD21 and HLA-II double-positive (C) 
were quantified by flow cytometry. Whole cell lysates from stably transfected 
empty vector or TRIM22 transfected single-cell clones were probed for TRIM22 
and β actin by immunoblotting (D). Percentage of live EBV-GFP cells in empty 
vector and TRIM22 cells were quantified 5 dpi. Matched clones are connected 
with lines (E) (n=4). Control- or TRIM22- siRNA transfected HFFs were infected 
with HCMV Ad 169 at a MOI of 1 and virus yields were measured by plaque 
assays on HFFs at 72hpi (F) (n=3). HEK293 cells stably transduced with either 
the empty vector or the full-length TRIM22 vector were infected with VSV-GFP at 
a range of dilutions from 0 to 2.5x106 pfu/ml, and assessed by flow cytometry for 
live, infected cells at 16hpi (G) (n=3). (P<0.05*, Student’s t-test). 
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Figure 2.13 (Continued) 
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Discussion 
TRIM22 as a restriction factor of HSV-1 by epigenetic regulation of viral 
genes 
HSV-1 restriction in the nucleus has been previously ascribed to 
components of ND10 bodies in the nucleus consisting of TRIM19/PML, hDaxx, 
Sp100 [42,149,150], and to nuclear IFI16 [143,151]. We add TRIM22 to this list 
by demonstrating that TRIM22 is necessary and sufficient for restriction of HSV-1 
inhibition. TRIM22 depletion in fibroblasts rescued the replication of an ICP0-l 
virus and to a smaller extent, an ICP0+ virus. The inhibition of both the ICP0- and 
ICP0+ viruses in TRIM22 over-expression studies in HeLa cells further 
corroborates this finding. Interestingly, the magnitude of TRIM22-mediated 
inhibition of HSV-1 in HeLa cells is smaller at high MOIs, reflecting a MOI-
dependent effect where the virus is capable of overcoming the intrinsic restriction 
at high MOIs in HeLa cells. This MOI-dependent effect on viral restriction is a 
common feature of intrinsic immunity and was previously reported in the rhesus 
macaque TRIM5α mediated restriction of HIV-1 [73,152].  
TRIM22 was previously shown to inhibit viruses by various mechanisms, 
including degradation of viral proteins, as seen in EMCV [109] and IAV [91], 
transcriptional repression [107,108] and inhibition of viral assembly [94], as seen 
in HIV-1, and prevention of viral core promoter activity, as seen in HBV [110]. We 
discovered that the TRIM22-mediated inhibition of HSV-1 replication was due to 
a defect in viral IE gene expression after nuclear entry of viral genomes, with 
downstream effects on E gene expression, viral DNA synthesis and L gene 
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expression. The mechanism of inhibition is novel in that TRIM22 depletion 
reduces histone occupancy and heterochromatin marks on viral DNA; chromatin 
modification as a means of viral inhibition has been directly attributed to IFI16 
[143], and ATRX in concert with hDaxx to a smaller extent, as a chromatin 
remodeling complex [42]. The significance of this finding is implicated in a review 
by Hattlman, CJ [153] who hypothesized that TRIM22 could contribute to viral 
latency based on the observations that (i) the EBV Latent Membrane Protein 1 
(LMP1) required for EBV latency upregulates TRIM22 [112] and (ii) KSHV LANA 
protein upregulates TRIM22 in vitro and in KSHV lesions [111]. In both cases, 
TRIM22 was upregulated by viral proteins associated with latency and this was 
proposed to prevent super-infection by other viruses [111,112]. However, a 
mechanism for this connection to latency has not been determined. Thus, it was 
of interest to us that TRIM22 epigenetically regulates viral gene expression by 
the observed decrease in histone occupancy in the absence of TRIM22 and the 
reduction in heterochromatin and facultative heterochromatin marks on viral gene 
promoters in lytic infection. Further studies need to be done on whether TRIM22 
can contribute to viral latency by modifying chromatin. 
 
TRIM22 restricts viruses that replicate in the nucleus 
The importance of nuclear-specific inhibition of HSV-1 was evident from 
PML, Daxx, Sp100 and ATRX in ND10 bodies [42,150], and IFI16 [143], which 
are crucial for nuclear-specific inhibition of HSV-1. In addition, the endogenous 
nuclear localization of TRIM22 in primary fibroblasts, where the inhibitory effect 
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of TRIM22 was observed, lends further evidence to the case for recognition and 
restriction of foreign DNA in the nucleus. This report expands the anti-viral 
specificity of TRIM22 to include viruses with dsDNA genomes that replicate in the 
nucleus, the herpesviruses. 
As mentioned previously, the TRIM22-mediated anti-viral mechanisms of 
inhibition of other viruses can be predominantly attributed to its E3 ubiquitin 
ligase activity located in the N-terminal RING domain of the protein [91,109,110]. 
In the case of HSV-1, the formation of nuclear punctae seems equally as 
important as the E3 ubiquitin ligase activity of TRIM22 for the anti-viral effect, as 
the absence of the RING domain or the inactive RING-domain mutant, TRIM22-
C15A, C18A only partially alleviated the TRIM22-mediated restriction of HSV-1. 
In contrast, the deletion of the SPRY domain significantly reduced TRIM22-
mediated restriction and therefore this domain is also required for mediating the 
antiviral activity. 
In fact, the SPRY domain of TRIM22 has been implicated in the protein’s 
subcellular localization as evidenced by the following key observations in the 
literature: (i) The absence of B30.2/SPRY domains in a transfection system 
prevents the formation of nuclear punctae [142], (ii) B30.2/SPRY domain swaps 
between human and rhesus TRIM22 proteins alters the subcellular localization of 
these proteins [154]. In addition, the importance of the SPRY domain was also 
evident in TRIM22’s anti-viral activity, in that, the absence of the SPRY domain 
was shown to abrogate the inhibition of HBV [110]. Interestingly, the construct 
lacking the SPRY domain localized primarily to the cytoplasm, in a location 
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different from the nuclear-replicating HBV [110]. The phenotype of the ΔSPRY 
domain mutant in HSV-1 infection is similar. These results are suggestive of the 
importance of nuclear localization or other intranuclear activity of TRIM22 in the 
inhibition of viruses that replicate in the nucleus, such as other herpesviruses.  
Therefore, TRIM22 inhibits viruses that replicate in the nucleus: IAV [91], 
HBV [110], and in this study herpesviruses including members of the α, β and γ 
Herpesviridae, while it is unable to restrict viruses that replicate in the cytoplasm 
such as VSV, a RNA virus. On the other hand, TRIM22 also inhibits EMCV, a 
positive strand RNA virus that replicates in the cytoplasm [109]. However, these 
studies were conducted in transient transfection settings where the protein can 
potentially show cytoplasmic localization and suggest that TRIM22 may also 
have a role in the cytoplasm. This is consistent with the activity of other 
restriction factors that localize to and inhibit pathogens in particular 
compartments.  
 
HSV-1 mediated escape of TRIM22-mediated inhibition 
We attribute the ability of the wild-type virus to overcome TRIM22-
mediated inhibition to the viral IE protein, ICP0. ICP0 is crucial to alleviating a 
majority of the intrinsic- and the Type I IFN mediated- immune responses: i.e., (i) 
it disrupts PML bodies at sites of viral replication [155], preventing their intrinsic 
inhibition; (ii) it sequesters phosphorylated IRF3 from the nucleus [128,156], thus 
preventing its activity as a transcription factor and (iii) it degrades the nuclear 
viral DNA sensor and intrinsic resistance factor, IFI16, thus preventing detection 
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and silencing of viral DNA [30]. Therefore, the finding that ICP0 rescued most of 
the intrinsic block by TRIM22 is consistent with previous studies. However, this 
reduction in inhibition is not due to the ICP0-mediated degradation of TRIM22, as 
viruses with ICP0 such as the 7134R and the d106 viruses did not degrade 
TRIM22 (Figure 2.5, Results not shown). Surprisingly, TRIM22 is not degraded 
by ICP0, and it remains to be determined how the virus evades the intrinsic 
restriction activity of TRIM22 and whether there are other viral factors that 
antagonize TRIM22.  
In conclusion, the key features of restriction factors are that they (i) are 
germline-encoded, expressed constitutively, and often interferon (IFN)-inducible; 
(ii) demonstrate atypical mechanisms of viral inhibition and; (iii) show hallmarks 
of positive genetic selection (high dN/dS ratios) reflecting host-pathogen co-
evolution [39]. Consistent with previous reports, we show that TRIM22 is IFN-
inducible, restricts HSV-1 in an epigenetic fashion, and was demonstrated to 
have a high dN/dS ratio by other laboratories [116]. Thus, we report that TRIM22 
is a novel restriction factor of HSV-1. We also report that this restriction is 
mediated by epigenetic silencing of viral gene expression, and the detailed 
mechanisms of TRIM22 mediated repression of viral DNA remain to be further 
explored.  
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Abstract 
 Variation in genes encoding restriction factors, such as non-synonymous 
single nucleotide polymorphisms, can alter the anti-viral functionality of those 
proteins. The genetic variation in the TRIM5 and TRIM22 gene neighbors was 
previously attributed to the lentiviruses, such that these two genes were mutually 
selected for in different primate lineages throughout evolution. Our collaborators 
characterized novel variation at the TRIM22 locus, or seven TRIM22 haplotypes. 
They identified four single nucleotide polymorphisms encoding non-synonymous 
amino acid substitutions in the linker L2 and coiled-coil domains of TRIM22. We 
demonstrate that the asparagine to aspartic acid amino acid substitution at 
position 155 in the coiled-coil domain of TRIM22 reduce correlates of EBV 
infection in vitro, in silico and in vivo. We also show that the threonine to arginine 
substitution at position 242 in the linker L2 domain reduce HSV-1 viral yields in 
vitro. Therefore, we hypothesize that the haplotypic diversification observed in 
TRIM22 is an example of the host-virus arms race in primate evolution, and 
propose that the TRIM5 and TRIM22 gene neighbors evolved due to selective 
pressure from both herpesviruses and lentiviruses. 
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Introduction 
Non-synonymous single nucleotide polymorphisms (nsSNPs) in genes 
alter not only the amino acid composition of the proteins they encode, but can 
also change their structure and function. In fact, approximately 50% of inherited 
genetic diseases have mutations associated with nsSNPs [157-159]. Mutations in 
innate immune genes have also been associated with a variety of inflammatory 
disorders, including asthma [160], tuberculosis [161], and many others (reviewed 
in [162]). 
Genetic variation in host innate immune proteins can also alter the host’s 
susceptibility to pathogens such as viruses. For instance, many of the genetic 
variations in the TRIM family of proteins have been shown to affect their antiviral 
specificity. In particular, amino acid substitutions in the coiled-coil, B-box, linker 
L2 and the C-terminal B30.2/SPRY domains in both the TRIM5 and TRIM22 
proteins have been shown to affect the structure, function, and antiviral specificity 
of these proteins [55,78-82,91,92,108-110,142,163,164]. This genetic variation 
observed in the TRIM5 and TRIM22 gene loci has been attributed to evolutionary 
pressures exerted by retroviruses [114,116].  
 Amino acid substitutions in the coiled-coil and linker L2 domains in 
TRIM5α from rhesus macaque monkeys (rhTRIM5α) have been shown to alter its 
antiviral activity [165]. This is possibly because the coiled-coil domain of 
rhTRIM5α is important for higher-order multimerization and mediates its 
specificity to binding lentiviral capsids [73,165,166].  Additionally, variation in the 
B30.2/SPRY domain of TRIM5α has been shown to change its activity against 
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HIV-1 and herpesviruses [55,75,77,82,86,114,167-175]. Prior work conducted in 
the Letvin laboratory demonstrated that B-lymphoblastoid cell lines (B-LCLs) of 
rhesus macaque monkey origin expressing TRIM5 haplotypes encoding the wild-
type B30.2/SPRY domain, were significantly more permissive to β-herpesvirus, 
rhesus cytomegalovirus (rhCMV), and γ-herpesvirus, rhesus lymphocryptovirus 
(rhLCV), infections than B-LCLs encoding TRIM5 genes with a 2-amino acid 
deletion in the B30.2/SPRY domain [86]. These in vitro differences correlated 
with an in vivo study measuring antibody titers against rhCMV and rhLCV [86]. 
However, no significant differences in the antiviral activity of the TRIM5 
haplotypes were observed with two other DNA viruses, adenovirus 5 (Ad5) and 
simian vacuolating virus 40 (SV40), suggesting that this TRIM5 haplotypic 
variation in anti-viral activity is specific to the rhesus macaque herpesviruses 
[86]. Other important genetic variations in TRIM5 include polymorphisms that 
result in H43Y, R136Q, and G249D amino acid substitutions that confer 
variability to HIV-1 acquisition and disease progression in human patients 
[84,176-178].   
The closest human paralog of TRIM5 is TRIM22 [116]. The TRIM22 gene 
locus has undergone episodic positive evolutionary selection, as evidenced by a 
positive dN/dS ratio in Old World Monkeys, and hominoids including humans 
[116]. This positive selection resulted in TRIM22 variation at the level of SNPs, 
which have been shown to be associated with functional anti-viral significance 
[179]. The characterized variation in TRIM22 that alters its antiviral function 
include the following SNPs: rs10838543 T/C (position 364), rs7935554 A/G 
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(position 463) and rs1063303 C/G (position 242) [180]. For example, HIV-1 
replication was higher in PBMCs from human donors homozygous at SNPs 
rs7935564 G/G and rs1063303 G/G [164]. In contrast, the TRIM22 SNP 
rs1063303 C/C decreased TRIM22’s antiviral function against HIV-1 [181]. 
Furthermore, the TRIM22 rs10838543 C/C genotype in the Han-Chinese 
population is associated with chronic HBV infection [182].  
Further predicted SNPs within the TRIM22 gene were identified by in silico 
analyses across multiple databases [163]. A summary of the nsSNPs encoding 
the amino acid substitutions that are predicted to be functionally important follow: 
L68R and H73R in the linker L1 region, E135K in the coiled-coil region, I234N 
and S244L in the linker L2 region, G346S, K364N, P403T, K364N, P403T, 
L432W, R442C, F456I, T460I, P484S and C494F in the B30.2/SPRY domain 
[163]. Although this study demonstrated that the amino acid substitutions disrupt 
the structure of the TRIM22 B30.2/SPRY domain, no functional characterization 
was conducted on these amino acid substitutions.  
These studies provide a strong evidence for the functional role and the 
importance of genetic variations in the genes encoding host viral restriction 
factors like the TRIM proteins. Here, we report here that the haplotypic variation 
in the TRIM22 gene locus as identified by our collaborators [183], altered the 
anti-herpesviral activity of TRIM22 in in vitro replication studies. We further 
hypothesize that the haplotypic variation in TRIM22 correlates with herpesviral 
loads in humans. Consequently, we speculate that the genetic variation observed 
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at the TRIM22 gene locus is due to evolutionary pressure exerted by 
herpesviruses, in addition to the previously known retroviruses.  
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Materials and Methods 
Cell Culture. HEK293, HeLa and CF2TH cells were obtained from the American 
Type Culture Collection (ATCC). HEK293 cells stably transduced with CD21 and 
HLA-II were obtained from the Fingeroth laboratory and cultured as described 
previously [138]. CF2TH cells stably transduced with human TRIM22 genes were 
obtained from the Letvin laboratory at Harvard Medical School and cultured in 
DMEM with 10% FBS and 4ug/ml puromycin [183].  
 
Virus Infections. EBV-GFP was diluted in DMEM with 10% FBS and Pen-Strep. 
EBV-GFP stocks were prepared from a cell line kindly donated by Wolfgang 
Hammerschmidt as described previously [141]. The virus was diluted in DMEM 
containing 10% FBS and the cells were infected for 5 days at 37°C. VSV-GFP 
was used according to described protocols and was a kind gift from Sean 
Whelan [184]. 
 
Plasmids and DNA Transfection. The TRIM22 cDNA was extracted from B 
lymphoblastoid cell lines from the Hap Map project and cloned into the pLPCX 
vector backbone (Clontech). HeLa cells were transfected with Effectene reagent 
and then infected at 24h after transfection. CF2TH cells stably transduced with 
the different TRIM22 haplotypes are a kind gift from So-Yon Lim. 
 
Western Blots. Cells were lysed in NuPAGE LDS Sample Buffer, and proteins 
were resolved on NuPAGE 4% to 12% Bis-Tris gels (Invitrogen) [143]. Proteins 
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were transferred overnight to nitrocellulose membranes and blocked with 5% milk 
in phosphate buffered saline (PBS) solution containing 0.1% Tween-20 (PBS-T). 
Membranes were probed with primary antibody at 4°C overnight, washed with 
PBS-T and incubated in secondary antibody for 1h at room temperature. Western 
blots were developed using the Super Signal Pico Chemiluminescence substrate.  
 
Flow Cytometry. HEK293 cells infected with EBV-GFP or VSV-GFP were 
trypsinized, collected by centrifugation and resuspended in solution containing 
Aqua-Amine (Life Technologies). Cells were washed twice in PBS and 
resuspended in 2% paraformaldehyde for 15 minutes at 4°C. The cells were 
analyzed using a LSR II flow cytometer and live cells were gated for using an 
Aqua-Amine negative gate after exclusion of doublets on forward and side 
scatter axes. GFP+ gate was defined on mock-infected cells. Data analysis was 
performed using FlowJo (version 8) software and graphs were constructed by 
using Graph Pad Prism software.  
 
In silico analyses of EBV genome copy numbers. Frequencies of TRIM22 
SNPs in HapMap B-LCLs were obtained from the dbSNP (Short Genetic 
Variations) from the NCBI database, using the specific rsSNP IDs assigned to 
different single nucleotide polymorphisms (http://www.ncbi.nlm.nih.gov/SNP/).  
The B-LCLs in the HapMap consortium originate from 4 different ethnic groups: a 
cohort of 30 trios (90 individuals) from Yoruba in Ibadan, Nigeria (YRI); a cohort 
of 30 trios from Utah with Northern and Western European ancestry (generated 
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at the Centre d’Etude Polymorphisme, CEU); from a cohort of 45 Japanese in 
Tokyo, Japan (JPT) and a cohort of 45 self-identified Han Chinese in Beijing, 
China (HCB) [180]. EBV genome copy numbers in B-LCLs were obtained from 
the Broad institute website 
(http://www.broadinstitute.org/mpg/pubs/hapmap_cell_lines/). All graphs were 
constructed using Graph Pad Prism software. 
 
Antibody titers. Plasma samples from a cohort of 45 Malawi patients were 
titered on anti-EBV VCA IgG ELISA kits from Abcam (ab108730). Briefly, five 10-
fold dilutions of plasma were added to ELISA plates pre-coated with Epstein-Barr 
antigen, followed by washing with phosphate buffered saline (PBS). Anti-human 
IgG labeled HRP was added to the plates. A colorimetric assay was conducted 
following catalysis of blue tetramethylbenzidine (TMB) to a yellow acidic solution 
after adding the stop solution. Controls included were a standard curve, EBV IgG 
cutoff control, EBV IgG negative control and EBV IgG positive control. The 
antibody absorbances were measured at OD450nm using an ELISA plate reader.  
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Results 
The TRIM22 linker L2 domain mediates variation in susceptibility to HSV-1. 
Previous studies showed that non-synonymous amino acid substitutions in 
the TRIM22 protein reduced its ability to inhibit HIV-1, and individuals 
homozygous for CC at rs10838543 in the RING domain of TRIM22 were 
associated with chronic Hepatitis B virus (HBV) infection [163,164,181,182]. In 
order to characterize the genetic variation in TRIM22, our collaborators 
sequenced the TRIM22 gene loci in B-LCLs generated from the Caucasian and 
Yoruba cohorts in the HapMap project [180]. They identified seven TRIM22 
haplotypes in these populations with the following nsSNPs encoding amino acid 
substitutions: rs7935564 A/G (N155D), rs1066303 G/C (T242R), rs61735273 C/T 
(S244L), rs730404240 C/A (T294L) (Figure 3.1A) [183]. The resultant amino acid 
substitutions are located in the coiled-coil domain and in the linker L2 domain of 
the TRIM22 protein (Figure 3.1B).  
To characterize whether the TRIM22 haplotypic variation alters 
susceptibility to HSV-1, we generated CF2TH cells or canine thymocyte cell 
lines, stably transduced with either an empty vector or each of the seven different 
TRIM22 haplotypes. We infected these cells with HSV-1 7134R at a MOI of 0.1 
and assessed viral yields at 48 hpi. We observed that TRIM22 haplotypes 5, 6 
and 7 all reduced 7134R yields relative to empty vector transfection, but TRIM22 
haplotype 6 showed a significant reduction in viral yields (Figure 3.1C). When we 
measured the level of protein expression of the transfected TRIM22 haplotypes, 
we observed that haplotypes 6 and 7 were expressed at lower levels than the 
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rest (Figure 3.1D).  Despite their lower level of expression, haplotypes 6 and 7 
decreased viral replication, arguing that these TRIM22 haplotypes are potentially 
more restrictive to HSV-1 infection in vitro relative to the rest of the haplotypes. 
To confirm the TRIM22 haplotype-mediated variability in HSV-1 
susceptibility in another system, we transfected HeLa cells with either the empty 
vector or the vectors encoding each of the different TRIM22 haplotypes. We then 
infected the cells with HSV-1 7134R at a MOI of 0.1 and measured viral yields at 
48 hpi. Consistent with the results from the CF2TH cells, HeLa cells transfected 
with TRIM22 haplotypes 5, 6 and 7 showed lower viral yields relative to the 
empty vector transfected cells (Figure 3.1E). It must be noted that the level of 
restriction observed in HeLa cells was lower compared to the CF2TH cells, 
possibly due to the transient transfection system in HeLa cells versus the stable 
transduction in CF2TH cells (Figure 3.1E). TRIM22 haplotypes 6 and 7 showed 
lower levels of protein expression in HeLa cells relative to the other haplotypes 
consistent with the expression levels seen in the CF2TH cells (Figure 3.1F). 
Together, these results demonstrate that TRIM22 haplotypes 6 and 7 encoding 
the amino acid arginine at position 242, amino acid leucine at position 244 and 
threonine at position 294 are more restrictive than other haplotypes. In addition, 
these results suggested that variation in the TRIM22 gene locus could play a role 
in the susceptibility to HSV-1 infection in humans. 
 
 
 
	   	   	   	   	   	  
 84 
Figure 3.1: TRIM22 haplotypes alter susceptibility to HSV-1. Full-length 
TRIM22 cDNAs were prepared from the human lymphoblastoid cell lines (B-
LCLs) in the Caucasian and Yoruba cohorts generated in the HapMap project 
and sequenced. The resulting TRIM22 haplotypes were labeled in descending 
order of frequency in the whole population (A). The schematic diagram shows the 
location of the amino acid substitutions when mapped to the predicted domain 
structure of the TRIM22 protein (B). CF2TH cells stably transduced with an 
empty pLPCX vector control (EV) or the pLPCX vectors with TRIM22 haplotype 
insert (1, 2, 3, 4, 5, 6 and 7) were infected with HSV-1 7134R at 0.1 MOI. Viral 
yields were measured by plaque assays at 48hpi (n=3) (C). Representative 
western blot showing whole cell lysates probed for TRIM22 and GAPDH levels 
(D).  HeLa cells transfected with an empty pLPCX vector control (EV) or the 
pLPCX vector with TRIM22 haplotype insert (1, 2, 3, 4, 5, 6 and 7) were infected 
with HSV-1 7134R at an MOI of 0.1. Viral yields were determined at 48 hpi by a 
plaque assay on U2OS cells, (n=5) (E). Representative western blot showing 
total cell lysates probed for TRIM22 and GAPDH protein levels (F).  
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TRIM22 coiled-coil domain mediates variation in susceptibility to EBV. 
Our collaborators and others described a nsSNP in TRIM22 encoding an 
N155D amino acid substitution in the coiled-coil domain [180,183]. Given that the 
coiled-coil domain has been shown to be important for higher-order 
multimerization and antiviral activity in some TRIM proteins, we wanted to identify 
whether the SNP encoding an N155D amino acid substitution in the TRIM22 
coiled-coil domain altered the antiviral activity of TRIM22 [165]. We stably 
transduced CD21- and HLA-II-expressing HEK293 cells with full-length TRIM22 
haplotypes encoding either an asparagine (TRIM22 N155) or an aspartic acid 
(TRIM22 D155) at position 155, or with a control pLPCX vector, and assessed 
the efficiency of a γ-herpesvirus, or EBV infection. The cell lines were infected 
with EBV-GFP at MOIs up to 17 green Raji units/ml [185]. Both TRIM22 N155- 
and TRIM22 D155- transduced cell lines demonstrated fewer EBV-GFP+ cells 
than the empty control vector-transduced HEK293 cells (Figure 3.2A). Moreover, 
TRIM22 D155-transduced HEK293 cells demonstrated consistently fewer EBV-
GFP+ cells compared to HEK293 cells expressing TRIM22 N155 at (Figure 3.2A). 
Lysates prepared from the TRIM22-transduced cells showed equivalent TRIM22 
expression levels by immunoblotting (Figure 3.2B). Transduction of the TRIM22 
constructs into the HEK293 cells did not alter EBV receptor levels, CD21 and 
HLA-II, based on comparison of three separate clones of transduced cell lines 
(Figure 3.2C). In contrast, similar percentages of VSV-GFP+ cells were observed 
in HEK293 cell lines transduced with either of the TRIM22 variants or the empty 
pLPCX control vector (Figure 3.2D). These results indicated that modification of 
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an N to a D at position 155 in the coiled-coil domain of TRIM22 produces a small, 
but consistent decrease in the efficiency of EBV infection in vitro. These results 
also suggest that this amino acid residue may play a role in the anti-viral activity 
of TRIM22 by altering potential multimerization of TRIM22, as has been 
demonstrated for rhTRIM5α [94,165,186,187].  
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Figure 3.2: The N155D amino acid substitution in TRIM22 decreases the 
efficiency of EBV-GFP infection in vitro. HEK293 cells stably expressing 
CD21 and HLA-II were transduced with TRIM22 constructs encoding an 
asparagine at amino acid position 155 (TRIM22 N155, filled circles) or TRIM22 
encoding an aspartic acid at position 155 (TRIM22 D155, filled squares) or the 
empty pLPCX vector (hollow diamonds). Cells were infected in triplicates with an 
EBV-GFP construct for 48h and live, GFP+ cells were measured by flow 
cytometry (A). The expression of TRIM22 protein by the transduced cells was 
determined by immunoblotting using an anti-TRIM22 antibody. Levels of β actin 
were assessed as a loading control (B). The expression of CD21 and HLA-II was 
assessed prior to infection with EBV-GFP (C). TRIM22 N155, TRIM22 D155 and 
empty vector transduced HEK293 cells were infected with a VSV-GFP construct 
for 6h using serial dilutions of virus and analyzed by flow cytometry (D). Error 
bars represent standard deviation of the GFP+ cells. (**P<0.01, ***P<0.001 Two-
way ANOVA with Bonferroni tests).  
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Figure 3.2 (Continued) 
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TRIM22 SNP variation correlates with EBV genome loads in B-LCLs 
   Because TRIM22 decreased the efficiency of EBV infection in vitro, and 
particular SNPs in TRIM22 alter this efficiency, we next sought to determine the 
distribution of TRIM22 SNPs in different ethnic populations in order to evaluate 
an indirect correlate of EBV infection, or a measurement of the EBV genome 
copy number in B-LCLs. The literature is unclear as to which B-LCL clone grows 
out in a group of EBV-transformed B cells [188], the number of virions required to 
transform a B cell, the basis of inheritance of the EBV copies and what controls 
the amplification of the EBV genome upon transformation. It is known that upon 
infection, linear EBV genomes circularize to form the episomes characteristic of 
latency approximately 20h post infection [189]. Although it is suggested that this 
one episome converts to a closed covalent circle around 36h post-infection, the 
copy number of EBV latency is restricted to 1-5 copies/cell. In addition, the large 
variation in copy number is also due to a 100-1000x amplification of the genome 
during latency. 
Thus, we first determined whether there was a difference in the frequency 
of the TRIM22 SNPs across different ethnic groups prior to assessment of EBV 
genome copy numbers in B-LCLs. To do so, we assessed previously available 
information available on B-LCLs from the HapMap consortium [180]. The 
HapMap B-LCLs originated from 4 different ethnic groups as described in the 
methods: Yoruba (YRI), Caucasians (CEU), Japanese (JPT) and Han-Chinese 
(HCB). These B-LCLs were previously genotyped by the HapMap consortium at 
two SNPs at the TRIM22 locus, rs7935564 encoding an asparagine to aspartic 
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acid amino acid substitution at position 155 (N155D) in the coiled-coil domain, 
and rs1063303 encoding a threonine to arginine amino acid substitution at 
position 242 (T242R) in inker L2 domain of TRIM22 [180]. The HapMap database 
did not have information for the two SNPs rs61735273 (S244L) and rs73404240 
(T294L), encoding amino acid substitutions in the linker L2 domain. The HapMap 
database was then analyzed to determine the frequencies of the nsSNPs 
encoding the N155D and T242R amino acid substitutions in TRIM22 in the 4 
ethnic groups.  
We observed that the frequencies of individuals homozygous for D at 
amino acid position 155 in TRIM22 (D/D) or R at amino acid position 242 in 
TRIM22 (R/R) varied between the ethnic groups. The HCB and JPT cohorts both 
had higher frequencies of D155D and R242R homozygotes than the CEU and 
YRI groups. This difference between the ethnic groups was more profound when 
comparing homozygotes for TRIM22 D155D (HCB= 72.1%, JPT = 61.6%, CEU = 
12.4%, YRI = 22.3%) than homozygotes for TRIM22 R242R (HCB=66.7%, JPT= 
79.5%, CEU = 31.7%, YRI = 45.0%). 
Because reports in the literature suggest there are potential cellular 
factors that influence EBV genome copy number in B-LCLs [190,191], we 
evaluated whether TRIM22 SNPs could contribute to differences in EBV copy 
numbers in B-LCLs. A study conducted by Choy et al. (2008) measured EBV 
copy numbers in DNA extracted from HapMap B-LCLs by qPCR for the EBV 
DNA polymerase gene BALF5 [192]. The average values of the EBV copy 
numbers were calculated for each ethnic group. The HCB and JPT ethnic groups 
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had mean EBV genome copy numbers of 0.28 and 0.15 copies per cell, 
respectively, whereas the CEU and YRI ethnic groups had higher mean EBV 
genome copy numbers of 2.11 and 0.69 copies per cell, respectively (Figure 3.3). 
Therefore, the genetic variation in TRIM22 across ethnic groups correlates with 
the mean EBV genome copy numbers in B-LCLs from these ethnic groups. 
Specifically, the HCB and JPT groups that have higher frequencies of 
homozygotes encoding D155D and R242R also had lower EBV genome copy 
numbers in B-LCLs in comparison to the CEU and YRI ethnic groups.  
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Figure 3.3: EBV genome copy number differs in B-LCLs from different 
cohorts. The EBV genome copy numbers as measured by qPCR for BALF5 by 
Choy E., et al., in B-LCLs from a cohort of 30 trios (90 individuals) from Yoruba in 
Ibadan, Nigeria (YRI); a cohort of 30 trios with Utah with Northern and Western 
European ancestry (generated at the Centre d’Etude Polymorphisme, CEU); from 
a cohort of 45 Japanese in Tokyo, Japan (JPT) and a cohort of 45 self-identified 
Han Chinese in Beijing, China (HCB) are shown.  
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We then compared the mean EBV genome copy numbers in B-LCLs from 
each ethnic group to the frequencies of homozygotes for D155D and R242R in 
each group (Figure 3.4A). We observed that the mean EBV genome copy 
numbers in B-LCLs correlated inversely with the frequency of individuals 
homozygous for TRIM22 D155D (Figure 3.4B) or TRIM22 R242R (Figure 3.4C) 
across the ethnic groups. We identified that a correlation between high TRIM22 
SNP frequencies encoding the N155D and the T242R amino acid substitutions 
and low EBV genome copy numbers was consistent even when the EBV genome 
copy numbers in the LCLs were measured at baseline and when the LCLs were 
expanded, but not when measured in a smaller sample size of biological 
replicates (Data not shown). 
At this point, it was unclear whether the lower EBV genome copy numbers 
were due to the ethnicity the B-LCLs originated from, or whether it was due to the 
TRIM22 genotype differences in these B-LCLs. Hence, we assessed the 
correlation between TRIM22 SNPs and EBV genome copy within the four ethnic 
groups, by subgrouping B-LCLs based on whether the TRIM22 gene locus was 
homozygous or heterozygous at amino acid residues at position 155 (N/D) and 
position 242 (R/T).  We observed that EBV genome copy numbers in the CEU 
cohort were approximately 2 copies per cell and were comparable between the 
different subgroups (Figure 3.4D). However, the EBV genome copy numbers 
were significantly different across TRIM22 genotypes in the YRI cohort, despite 
the lack of a clear stratification (Kruskal-Wallis test, P-value 0.0459) (Figure 
3.4E). This is possibly due to the significantly lower EBV genome copy numbers 
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in B-LCLs from TRIM22 D155D homozygotes versus the TRIM22 N155N 
homozygotes in the YRI cohort (Kruskal-Wallis test, P-value 0.0174) (Results not 
shown). Therefore, the inverse correlation of high frequencies of homozygotes 
encoding TRIM22 D155D or TRIM22 R242R with low mean EBV copy numbers 
was absent when the copy numbers were analyzed in relation to both these 
SNPs at the TRIM22 gene locus. Therefore, these results argue that there are 
other factors besides TRIM22 that affect EBV genome copy numbers in B-LCLs. 
However, in the HCB and JPT cohorts, there is a potential premise for 
evolutionary pressure on TRIM22, as both cohorts only had R242R 
homozygotes, with no other genotypes present in the sampled B-LCLs (Figures 
3.4F and 3.4G). Although this observation may be due to the smaller sample 
sizes of these ethnic groups than the CEU and YRI cohorts, it also hints at an 
evolutionary pressure that selects against the potentially more permissive 
TRIM22 T242T. Future studies should account for these sample sizes when 
investigating TRIM22 genetic diversity.  
These findings argued that the distribution of TRIM22 SNPs in the coiled-
coil and linker L2 domain differ between ethnic groups and initially suggested that 
these SNPs correlated with EBV genome copy numbers in B-LCLs from these 
groups. However, further analyses demonstrated that the ethnic origin of these 
B-LCLs is a better correlate for EBV genome copy numbers. This is consistent 
with the concept that multiple genetic traits are required to develop clear 
correlates for phenotypes, such as the maintenance of EBV genome copy 
numbers in B-LCLs. 
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This suggests that the in vitro culture conditions of the LCLs are variables 
that must be tightly controlled in future studies. This has also been demonstrated 
in a previous study that EBV DNA copy number fluctuates over time but stays in 
a constant range and does not correlate with culture conditions or cell density.  
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Figure 3.4: The frequency of TRIM22 SNPs correlates inversely with mean 
EBV genome copy number between different ethnic groups, but not within 
the ethnic groups. A schematic of TRIM22 with the amino acids of interest is 
shown (A). The mean EBV genome copy number in the CEU (red), YRI (purple), 
JPT (green) and HCB (blue) cohorts is shown relative to the frequency of D155D 
homozygotes (B) and R242R homozygotes (C) in these cohorts. The EBV 
genome copy numbers relative to the TRIM22 SNPs encoding either N/D at 
position 155 and either T/R at position 242 in the CEU (D), YRI (E), HCB (F), and 
JPT (G) ethnic groups is shown. P values were calculated using Kruskal-Wallis 
test with Dunn’s multiple comparisons t test. 
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Figure 3.4 (Continued) 
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TRIM22 SNP correlates with variation in anti-EBV antibody titers. 
Previous genome-wide association studies suggested that there is a 
correlation between specific genetic variation and anti-EBV antibody titers in vitro 
[193]. Upon measuring anti-EBV viral capsid antigen (VCA) IgG antibodies by 
ELISA in a cohort of patients from Malawi, we identified that patients 
homozygous for aspartic acid at position 155 (TRIM22 D155D) in the coiled-coil 
domain of TRIM22 had lower antibody titers compared to patients homozygous 
for asparagine at this position (TRIM22 N155N) (Figure 3.5). Although these 
results were consistent with the data observed in in vitro infections (Figure 3.2C), 
the interpretation was unclear. Prior literature suggests that seropositivity for anti 
VCA IgG titers alone is suggestive of a recent EBV infection or poorly functioning 
cellular immunity [194]. Further research that measures the anti-VCA IgM and 
anti-EBNA IgG titers must be conducted before drawing any conclusions from 
these titers. Therefore, these antibody titers are indicative of a past EBV 
infection, reactivation from latency, the immune status of these patients, or a 
combination of all or more of these factors.  
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Figure 3.5: Individuals encoding TRIM22 D155D have lower anti-EBV 
antibody titers than individual encoding TRIM22 N155N. Plasma from a 
cohort of patients in Malawi was assessed for anti-EBV viral capsid antigen 
antibody titers by ELISA and optical densities were measured. 
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Discussion 
Variation in TRIM22 linker L2 and coiled-coil domains alters host 
herpesviral susceptibility. 
We also identified that variation in the linker L2 domain and the coiled-coil 
domain of TRIM22 altered the target cell’s susceptibility to HSV-1 and EBV 
respectively. The linker L2 domain is arguably more important, as the TRIM22 
haplotypes encoding an arginine at position 242 demonstrated lower HSV-1 viral 
yields, and the only genotype present in B-LCLs from the HCB and JPT cohorts 
was homozygozity for R242R.  
Amino acid substitutions in the linker L2 domain have been shown to alter 
the function of TRIM proteins. This domain was demonstrated to be an important 
component for TRIM5 dimerization, in concert with the B-box 2 and coiled-coil 
domains [195]. Furthermore, an amino acid substitution from aspartic acid to 
glycine in the linker L2 domain of TRIM5 attenuated its anti retroviral activity 
against HIV-1 and HIV-2 in in vitro studies [195]. This amino acid substitution 
was also associated with higher HIV-1 susceptibility in Japanese and Indian 
populations [196]. In prior work on TRIM22, the arginine to threonine amino acid 
substitution at position 242 (R242T) has been associated with decreased anti-
HIV-1 activity [181]. 
Interestingly, the R242T amino acid substitution in the linker L2 domain 
changed the distribution of TRIM22 from nuclear punctae to diffuse localization in 
the nucleus and cytoplasm in transfected HeLa cells [181]. This is consistent with 
our observation that TRIM22 haplotypes 6 and 7, which encode R at position 
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242, with the adjoining leucine residue at position 244 and threonine residue at 
position 294, demonstrate greater restriction to HSV-1 infection in vitro relative to 
the other haplotypes or the empty vector. These results argue that it would be 
important to assess the subcellular localization of the different TRIM22 
haplotypes, particularly those encoding an arginine at position 242, when 
addressing their antiviral role in HSV-1 infection.  
Furthermore, the absence of the TRIM22 SNP encoding a threonine at 
position 242 in B-LCLs from the HCB and JPT populations suggests that these 
populations have a lower frequency of the more permissive TRIM22 SNP. This 
argues for the selection of “restrictive” TRIM22 haplotypes in these ethnic 
groups. However, increasing the power of these studies and conducting further 
validation studies will further inform this hypothesis. In summary, these findings 
all emphasize the importance of the amino acid substitutions in the linker L2 
domain in the anti-viral activity of TRIM22.   
There is a precedent for the importance of the coiled-coil domain in the 
anti-viral activity of the TRIM proteins. Amino acid residues in the coiled-coil 
domain of TRIM proteins, specifically in rhTRIM5α, have been shown to be under 
positive selection [197]. From studies on domain swaps in the rhTRIM5α protein, 
the coiled-coil region has been shown to be important in forming multimers, 
which is crucial for effective binding of rhTRIM5α to lentiviral capsids [57,198-
200]. This domain has been also shown to be important in mediating HIV-1 
capsid specificity [173,201]. However, one contrasting study suggests that the 
functional replacement of the coiled-coil domain of rhTRIM5α with the coiled-coil 
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domains of either the TRIM6 or TRIM34 paralogs maintains anti-HIV-1 activity 
[79]. 
We also provide further evidence for the functional importance of amino 
acid substitutions in the coiled-coil domain of TRIM22: (i) We identified that cells 
transduced with TRIM22 D155D show relatively lower efficiency of EBV-GFP 
infections in vitro relative to TRIM22 N155N, (ii) B-LCLs from ethnic groups with 
a higher frequency of individuals homozygous for TRIM22 D155D have lower 
EBV genome copy numbers on average and (iii) plasma from patients 
homozygous for D155D demonstrate lower anti-EBV VCA IgG antibody titers 
than patients homozygous for N155N. Although these are all indirect correlates 
of herpesviral infections and measure different parameters of the EBV replication 
cycle, we hypothesize that this amino acid substitution is important for TRIM22’s 
anti-viral activity.  
This data is inconsistent with the HSV-1 restriction observed in 
transfection systems with the TRIM22 haplotypes that encode an aspartic acid at 
position 155 in the coiled-coil domain, or TRIM22 haplotypes 2, 5 and 7. We 
reported that transfection of TRIM22 haplotypes 5 and 7 both lowered HSV-1 
yields relative to the empty vector. The TRIM22 haplotype 2, on the other hand, 
did not demonstrate HSV-1 restriction. Both TRIM22 haplotypes 5 and 7 encode 
an arginine at position 242 in the linker L2 domain, whereas TRIM22 haplotype 2 
does not. Therefore, two out of the three haplotypes that encode an aspartic acid 
at position 155 in the coiled-coil domain also encode the more potentially 
restrictive arginine at position 242 in the linker L2 domain. Both the haplotypes 
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that do so also demonstrate restriction against HSV-1. Therefore, it would be 
interesting to assess the importance of the arginine at position 242 in the linker 
L2 domain in TRIM22-mediated restriction activity against EBV. Further structural 
and functional studies assessing the individual and combined importance of 
these amino acids at these positions in the linker L2 and coiled-coil domains of 
TRIM22 are needed to interpret the anti-herpesviral role of TRIM22. 
In contrast to previous in silico analysis of the TRIM22 gene locus, which 
identified 9 nsSNPs in the B30.2/SPRY domain, it is noteworthy that the TRIM22 
variation was primarily in the linker L2 domain and the coiled-coil domain, in the 
traditional sequencing analysis of B-LCLs done by our collaborators. The only 
common nsSNP between these two studies is the S244L amino acid substitution 
in the linker L2 domain of TRIM22. Therefore, it is worth assessing the 
importance of this particular amino acid substitution in structural and functional 
studies of TRIM22.  
 
Co-evolution of the TRIM5 and TRIM22 gene loci with herpesviruses 
The Red Queen hypothesis proposed by Leigh Van Valen in 1973 argues 
that hosts must keep pace with competitors or risk facing extinction [202]. In the 
case of genetic variation, there is always an evolutionary advantage to be gained 
by innovation [203]. As such, the TRIM5 and TRIM22 gene neighbors evolved 
under positive selection in hominoids and Old World Monkey species, such that 
they were positively selected in different species [116]. The rhTRIM5α inhibits 
HIV-1 [152], whereas TRIM22 in humans shows significant HIV-1 inhibition 
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[94].Thus far, this discordant evolution in the TRIM5 and TRIM22 genes was 
attributed to coevolution of nonhuman primates with lentiviruses.  
This pattern is similar to what is observed in the anti-herpesviral activity of 
the TRIM proteins. We previously found that the rhTRIM5α protein was capable 
of cross-species restriction of human HSV-1 [135], and we report here that the 
human TRIM22 protein also has an ability to restrict human HSV-1. In contrast, 
human TRIM5 does not restrict herpesviruses as much as the rhTRIM5alpha 
[135]. These results suggest that TRIM22 is a functional anti-herpesviral and 
anti-retroviral TRIM protein in humans, consistent with this protein being 
positively selected for in hominoids.  
Further evidence for herpesviruses also exerting positive selection on 
TRIM proteins is evident in the TRIM22 haplotypes that show discordant 
antiretroviral and anti-herpesviral activity. We demonstrate that the seven 
different haplotypes of TRIM22 show varying degrees of HSV-1 inhibition. The 
nsSNP encoding the T242R amino acid substitution in the linker L2 domain of 
TRIM22 has previously been demonstrated to alter viral inhibition [93,163,164]. 
In the context of HIV-1, 293T cells transfected with TRIM22 haplotypes 
homozygous for R242R show a decreased capacity to inhibit HIV-1 transcription 
[164]. In addition, HeLa cells transfected with the TRIM22 R242R also did not 
inhibit HIV-1 Gag production relative to wild-type TRIM22 [94]. In contrast with 
HSV-1, we observed that HeLa cells and CF2TH cells transfected with TRIM22 
R242R inhibit HSV-1. These differences in the antiviral specificity exerted by 
these TRIM22 haplotypes encoding R242R further hint at evolutionary pressures 
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exerted on this gene locus by retroviruses and herpesviruses. Consequently, we 
speculate whether the dichotomy of the antiviral specificity of the TRIM5 and 
TRIM22 gene loci is pathogen-driven and due to selection pressures from 
herpesviruses, in addition to the previously known lentiviruses.  
There is a precedent for related genes that have different antiviral 
specificities despite being closely related. For example, the IFIT1 and IFIT2 
haplotypes recognize different caps on viral mRNAs, suggesting that the 
presence of alleles in this gene locus allows for antiviral specificity against 
unrelated RNA and DNA viruses [204,205]. We hypothesize that the TRIM22 
haplotypes we identified are examples of the arms race between host and 
pathogens, in this case, the relatively unrelated herpesviruses and retroviruses. It 
would be interesting to assess whether the TRIM22 haplotypes that restrict HSV-
1 are different from those haplotypes that restrict HIV-1. However, the 
mechanism for these differences in antiviral specificity is hard to interpret given 
that the herpesviruses and retroviruses differ in their major pathogen-associated 
molecular patterns and replication cycles. Further studies assessing the common 
targets between these two viruses should be conducted.  
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Chapter 4:  
CONCLUSIONS AND SIGNIFICANCE 
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4.1: Summary 
 This dissertation addressed the importance of human tripartite motif 22 
(TRIM22) in herpesviral infections, using herpes simplex virus 1 (HSV-1) as a 
primary example of this virus family. We report a novel host and virus interaction, 
the importance of the subcellular localization of this interaction, and show that 
genetic variation at the TRIM22 gene locus alters susceptibility to the 
herpesviruses. 
We reported that TRIM22 is a novel restriction factor against HSV-1. We 
also demonstrate that it significantly inhibits the replication of a mutant virus 
lacking the immediate-early viral E3 ubiquitin ligase, infected cell polypeptide 0 
(ICP0), crucial for HSV-1 replication. TRIM22 restricts ICP0-null virus replication 
by promoting heterochromatinization of viral genomes post nuclear-entry. This 
reduces viral gene transcription and expression, and consequently viral yields. It 
must be noted that the TRIM22-mediated restriction is overcome by the wild-type 
equivalent of HSV-1 in an ICP0-dependent, but a degradation-independent 
mechanism. This mechanism of viral escape of a host restriction factor is in 
contrast to the ICP0-mediated degradation of other known restriction factors, 
including TRIM19/PML, IFI16 and components of the DNA damage repair 
pathway. Hence, the wild-type equivalent of the virus has other ICP0-dependent 
mechanisms that overcome the restriction in a degradation-independent manner.  
Therefore, this work characterizes a novel interaction between the host intrinsic 
immune response and the virus. 
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The subcellular localization of the host surveillance system for 
herpesviruses has been a controversial topic recently. Host sensors of “non-self” 
DNA have been shown to be located in both the nucleus [30] and the cytoplasm 
[28], which was hard to corroborate with the nuclear location of herpesviral DNA 
recognition [206]. Our preliminary results suggest that the nuclear localization 
signal in the C-terminal B30.2/SPRY domain of TRIM22 is important for the 
inhibition of the nuclear-replicating HSV-1. This finding is yet another example of 
constitutively expressed host factors that target viral DNA upon nuclear entry in 
host cells. We also demonstrated that the TRIM22-mediated restriction is broader 
than previously known and show that it is capable of restricting other 
herpesviruses that replicate in the nucleus, including cytomegalovirus (CMV), a 
β-herpesvirus and Epstein-Barr virus (EBV), a γ-herpesvirus. However, it must be 
noted that TRIM22 has been shown to inhibit encephalomyocarditis virus 
(ECMV), a virus that replicates in the cytoplasm, suggesting that TRIM22 also 
has non-nuclear mechanisms of restriction. Overall, this work adds to the 
growing literature that addresses the importance of subcellular localization of 
anti-viral mechanisms implemented by the host.  
The importance of the host TRIM22 in host antiviral responses is also 
evident in the positive selection exerted on this gene [116], resulting in its 
haplotypic diversification. Our collaborators identified four non-synonymous 
single nucleotide polymorphisms (nsSNPs) encoding amino acid substitutions in 
the linker L2 and the coiled-coil domains of TRIM22. We report that the 
combination of an arginine at position 242, leucine at position 244 and threonine 
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at position 294 in the linker L2 domain are important for HSV-1 restriction. 
Preliminary results also demonstrate that the presence of an aspartic acid at 
position 155 in the coiled-coil domain associated with lowered correlates of EBV 
infection in in vitro and ex vivo studies. Therefore, this work suggests that the 
linker L2 and coiled-coil domains are a potential interface for interaction between 
herpesviruses and host TRIM22. Importantly, the mutations in the different 
TRIM22 haplotypes is another example of the ongoing arms race between host 
and viruses, with the TRIM proteins as representatives of the host side and the 
herpesviruses as mediators of the virus side of the conflict.  
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4.2: Discussion 
4.2.1: TRIM22 as a restriction factor 
4.2.1.1: How does TRIM22 inhibit HSV-1? 
The herpesviral genome consists of “naked” dsDNA that is not associated 
with proteins, as is traditionally seen with eukaryotic DNA. Although we 
demonstrated that TRIM22 promotes the compaction of viral DNA into 
nucleosomes, and modifies chromatin into inactive heterochromatin, the exact 
mechanism by which TRIM22 mediates these processes is unclear.  
An additional mechanistic concern is in the interpretation of the magnitude 
of the rescue in ICP0-null virus yields upon TRIM22 depletion, relative to the 
magnitudes observed for other restriction factors in the literature. The overall 
rescue in ICP0-null virus yields upon TRIM22 depletion is up to a 1000-fold. In 
contrast, the rescue in ICP0-null virus yields upon depletion of known restriction 
factors such as TRIM19/PML or IFI16 is only approximately 10-100 fold. In 
addition, the defect at each stage in the viral replication cycle due to TRIM22 is 
only approximately a few-fold. We propose two possible hypotheses for this 
degree in TRIM22-mediated rescue in viral yields.  
One hypothesis is that small effects at initial stages in viral replication, 
such as the observed reduction in histone occupancy on viral gene promoters, 
results in greater downstream defects on HSV-1 replication cycle. Another 
hypothesis is that TRIM22 restricts HSV-1 in an indirect pathway through one of 
the other well-known intrinsic resistance factors such as IFI16, TRIM19/PML in 
ND10 bodies, or a yet unknown factor. As mentioned earlier, further support for 
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this hypothesis is that the degree in rescue of the ICP0-null virus upon TRIM22 
depletion is substantially higher than what is observed upon depletion of each of 
these individual restriction factors of HSV-1[43,122]. The potential mechanisms 
and experiments that will address the latter hypothesis are discussed below. 
 
4.2.1.2: TRIM22 and IFI16 
 The interferon γ inducible protein 16 (IFI16) is an attractive candidate as 
an indirect mediator for TRIM22’s restriction activity for the following reasons: (i) 
Both TRIM22 and IFI16 have similar anti-herpesviral specificity against both 
HSV-1 and CMV. Our lab previously demonstrated that IFI16 restricts HSV-1, 
and we reported here that TRIM22 restricts HSV-1. IFI16 was shown to restrict 
CMV at an early stage in viral replication by impairing viral DNA synthesis after 
nuclear entry [207]. Although the TRIM22-mediated mechanism of CMV 
restriction is currently unknown, we demonstrated that TRIM22 depletion 
increased HCMV viral yields; (ii) Both TRIM22 and IFI16 have a similar anti-viral 
mechanism in HSV-1 infection- they interfere with viral gene expression by 
promoting heterochromatinization of viral DNA [43]; (iii) Both TRIM22 and IFI16 
localize to the nucleus, suggesting at a location-specific cooperation between 
these proteins; (iv) Although TRIM22 does not have a DNA-binding domain, 
IFI16 has demonstrated DNA-binding activity [208]. Based on the DNA-binding 
capacity of IFI16, we hypothesize that TRIM22 restricts HSV-1 through an IFI16-
mediated mechanism. 
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 Despite the earlier mentioned similarities between TRIM22 and IFI16, they 
differ in the mechanistic details of epigenetic silencing. In HSV-1 replication, 
incoming viral genomes initially are loaded with histones such as H3 to form 
nucleosomes. This is followed by post-translational modifications of the histone 
tails in nucleosomes to form inactive heterochromatin or active euchromatin. In 
the case of IFI16 depletion in primary fibroblasts, there are no observed changes 
in total histone H3, but there is an observed increase in euchromatin marks and 
decrease in heterochromatin marks on viral gene promoters [43]. In contrast, 
TRIM22 depletion reduces total histone H3 and reduces heterochromatin marks 
on viral DNA, with an insignificant trend in increased euchromatin marks on viral 
DNA. These results suggest a mechanistic quandary where the protein with the 
DNA-binding ability, or IFI16, does not alter initial histone H3 association on viral 
DNA. In contrast, TRIM22 alters histone H3 association despite the lack of a 
DNA-binding domain. 
 One possible explanation for these mechanistic differences between 
TRIM22 and IFI16 is that these restriction factors are temporally separated in 
their restriction. TRIM22 may initially act to compact viral DNA through a yet 
unknown DNA binding protein, followed by a synergy with the IFI16-mediated 
post-translational modification of histone tails to increase heterochromatinization 
and reduce euchromatinization of viral DNA. Furthermore, the effect of IFI16 on 
ICP0-null virus replication is more evident at low MOIs, whereas the TRIM22-
mediated rescue in ICP0-null virus replication is more evident at high MOIs in 
primary fibroblasts [43]. These results further suggest that it is unlikely that IFI16 
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is upstream of TRIM22. Therefore, future studies should address the effect of 
combined depletion of these proteins on viral yields at low MOIs to assess 
whether they synergize in their restriction abilities as hypothesized.  
 
4.2.1.3: TRIM22 and TRIM19/PML in ND10 bodies 
Although it is well established that ND10 bodies are recruited to incoming 
viral DNA genomes in the nucleus, it is unclear how exactly these nuclear 
structures mediate restriction [155,209-214]. This restriction is demonstrable by 
depletion of ND10 components such as tripartite motif 19 (TRIM19)/ 
promyelocytic leukemia protein (PML), speckled protein 100 (Sp100), Bloom 
syndrome helicase (BLM), hDaxx and α-thalassemia mental retardation X-linked 
(ATRX), which resulted in an increase in plaque-forming efficiencies and a 
rescue in herpesviral yields of mutant viruses [40,42,122,215-218]. TRIM19/PML 
is particularly important, as it is critical for the assembly of ND10 bodies [63]. 
Therefore, we speculated whether TRIM22 mediates its restriction activity 
through TRIM19/PML. 
The hypothesis that an interaction between TRIM22 and TRIM19/PML 
contributes to restriction of HSV-1 replication is attractive for the reasons that: (i) 
TRIM proteins are hypothesized to oligomerize through their coiled-coil domains 
[78,219] (ii) TRIM22 and TRIM19/PML are located in the nuclei of primary 
fibroblasts (Figure 2.4, [220]). TRIM22 has been shown to localize to nuclear 
Cajal bodies in certain cell types [221], and TRIM19/PML is critical for nuclear 
ND10 body formation [63]. Lastly, ND10 bodies are commonly associated with 
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Cajal bodies [222]. (iii) TRIM19/PML has been shown to mediate the anti-viral 
activity of exogenous interferon (IFN) in ICP0-null virus infections at low MOIs 
[223]. This is similar to our reported results at low MOIs- TRIM22 mediates a few-
fold rescue in viral yields of ICP0-null virus in Type I and Type II IFN pre-treated 
cells (iv) Both TRIM22 and TRIM19/PML have similar anti-herpesviral specificity. 
ND10 bodies, containing TRIM19/PML, have been implicated in the restriction of 
HSV-1, HCMV and EBV [214,224,225]. This is consistent with our results of 
TRIM22-mediated restriction of all three viruses. (v) TRIM19/PML depletion 
increases the viral yields of an ICP0-null mutant HSV-1, but not wild-type HSV-1 
[218]. This is similar to the phenotype observed upon TRIM22 depletion in ICP0-
null versus ICP0-rescued virus infections.  
A potential mechanism as to how TRIM22 mediates HSV-1 restriction 
through TRIM19/PML is that TRIM22 cooperates with TRIM19/PML to form 
higher-order multimers with TRIM19/PML. Hypothetically, this would stabilize 
TRIM19/PML. Given that TRIM19/PML is crucial for the assembly of the ND10 
bodies that localize to incoming viral genomes, we hypothesize that TRIM22 
depletion would result in the destabilization of ND10 bodies, preventing ND10 
function.  
A preliminary test of the potential relationship between TRIM22 and 
TRIM19/PML is to assess whether these proteins colocalize at endogenous 
levels, and also in the context of viral infections. However, the literature has 
conflicting results on whether TRIM22 localizes to TRIM19/PML in ND10 bodies, 
with no clear results showing colocalization of TRIM22 and TRIM19/PML in 
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immunofluorescence studies. One report claims in “data not shown” that there is 
no observed colocalization between TRIM22 and TRIM19/PML in ABC28 cells, a 
breast cancer cell line, in both basal and progesterone-treated cells [221]. 
Another dissertation claims that over-expressed TRIM22 colocalizes with PML in 
HT1080 cells, a fibrosarcoma cell line [226]. The endogenous localization of 
TRIM22 is also unclear- the localization of TRIM22 has been attributed to 
centrosomes [117] and to nuclear bodies that colocalize with Cajal bodies 
constituting of p80-coilin [221]. TRIM22 also has been shown to change 
subcellular localization depending on the cell cycle phase [221]. In our 
immunofluorescence studies, we have been limited in our testing of TRIM22 
subcellular localization by the lack of an effective antibody specific for 
endogenous TRIM22. To determine if there is any interaction between TRIM22 
and TRIM19/PML, it will be important to assess whether a tagged TRIM22 
construct and TRIM19/PML colocalize in immunofluorescence studies under 
conditions of ICP0-null virus and ICP0-rescued virus infections. Further co-
immunoprecipitation experiments should also assess for a direct interaction 
between TRIM22 and TRIM19/PML. 
A second means of interrogating the TRIM22 and TRIM19/PML 
relationship is by the measurement of ICP0-null HSV-1 viral yields upon 
depletion of these proteins. In preliminary studies, we depleted either TRIM22 or 
TRIM19/PML or both proteins, and assessed ICP0-null and –rescued viral yields 
in low MOI infections. We observed an additive effect on the rescue in ICP0-null 
virus yields upon depletion of both TRIM22 and PML, relative to either TRIM22 or 
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PML alone, in primary fibroblasts (Results not shown). These preliminary results 
suggest that TRIM22 and PML act in independent pathways in restricting the 
replication of the ICP0-null virus. These preliminary results also suggest that 
TRIM22 is unlikely to mediate HSV-1 restriction by PML; however, further 
experiments are needed to validate these results. In addition, other components 
of ND10 bodies, particularly hDaxx and ATRX, which have been shown to form a 
chromatin-remodeling complex in CMV restriction, should also be investigated 
[227].  
 
4.2.1.4: TRIM22 and TRIM28/KAP1 
  
4.2.1.4: TRIM22 and an unknown restriction factor 
Alternatively, TRIM22 may mediate its restriction activity through any of 
the other known or unknown factors that have anti-herpesviral restriction activity. 
A formal experiment to test this would be to pull down TRIM22 with antibodies 
specific to TRIM22 or a tagged construct, and conduct mass spectrometry on 
interacting partners in the context of mock-, ICP0-null and ICP0-rescued virus 
infections. The interacting proteins of interest likely to mediate anti-viral activity 
would be those that are mutually present or absent in ICP0-null virus infections 
relative to the other conditions. Given that TRIM22 alters histone occupancy and 
histone modifications on the viral genomes, it would be interesting to determine 
whether any of the pulled down proteins include chromatin-remodeling enzymes, 
which are important in the context of HSV-1 gene expression [48,130,228-230].  
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Another approach to assess how TRIM22 mediates its restriction is by 
addressing the relative importance of the different domains, or the RING, B-box, 
coiled-coil, the connecting linker L2, and B30.2/SPRY domains. We and others 
demonstrated that the presence of the B30.2/SPRY domain is important for the 
nuclear localization of TRIM22. Besides conferring a nuclear localization for 
TRIM22 to the same compartment as the nuclear-replicating herpesviruses, there 
may be other factors that argue for the importance of this domain [142]. In the 
case of rhTRIM5α, the B30.2/SPRY domain has been shown to be important for 
the anti-viral capsid specificity [77,173,174,231]. However, given the nuclear 
localization of TRIM22 in our system, it is unlikely that TRIM22 is mediating its 
anti-herpesviral activity by binding herpesviral capsid, which gets docked at 
nuclear pores during viral replication. The B30.2/SPRY domain in TRIM22 has 
predominantly shown to be important in mediating TRIM22’s role in NF-κB 
activation, suggesting that its role in innate immune activation may have a 
mechanistic role in HSV-1 inhibition.  
We also demonstrate that the linker L2 and coiled-coil domains are 
important for anti-herpesviral activity - an arginine at position 242, leucine at 
position 244 and threonine at position 294 in the linker L2 domain is important for 
HSV-1 restriction. We also show that the amino acid substitution from an 
asparagine to an aspartic acid residue at position 155 in the coiled-coil domain of 
TRIM22 impacts EBV restriction. There is precedent for the importance of the 
linker L2 and coiled-coil domains in TRIM-mediated restriction. In fact, mutations 
in the linker L2 domain with the adjoining coiled-coil domain of TRIM5α promote 
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the formation of α-helices in the protein. These α-helices facilitate higher-order 
multimerization, and the assembly of cytoplasmic TRIM5α structures crucial for 
HIV-1 restriction [78,232]. In our system, we observe that exogenously 
expressed TRIM22 forms nuclear bodies. Thus, we propose that these amino 
acid substitutions in the linker L2 domain and the coiled coil domain of TRIM22 
potentially increase the α-helical content in this protein. Subsequently, these 
secondary structures could promote higher order multimerization and the 
formation of nuclear bodies, important for HSV-1 restriction. Therefore, future 
immunofluorescence studies could address the subcellular localization of the 
different TRIM22 haplotypes encoding these amino acid substitutions. Additional 
circular dichroism studies assessing the impact of these amino acid substitutions 
on TRIM22 secondary structures could also be conducted.  
Notably, the TRIM22-mediated effect on HSV-1 restriction is not entirely 
abrogated by a RING domain deletion, or by the inactive E3 ubiquitin ligase 
mutant. This is in contrast to the previously known anti-viral activity of TRIM22, 
which in many cases is dependent on the E3 ubiquitin ligase activity of the RING 
domain [89-91,109]. Therefore, additional testing of whether the TRIM22 
mediated restriction of HSV-1 is abrogated under conditions of treatment with a 
proteasomal inhibitor or MG132 would provide further evidence on the 
importance of the RING domain and consequently, the E3 ubiquitin ligase 
pathway in this restriction.  
In order to identify novel TRIM22 interacting partners, future studies 
should assess the restrictive abilities of coiled-coil and linker L2 domain-deletion 
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mutants, and of mutants with specific amino acid substitutions demonstrated to 
be crucial for restriction. This would be followed up by pull-down studies 
comparing full-length TRIM22 versus deletion mutants lacking the domains or 
amino acid substitutions important for HSV-1 restriction to identify novel 
interactors. 
 
4.2.1.5: How does HSV-1 overcome the TRIM22-mediated restriction?  
It is interesting to note that the TRIM22-mediated restriction is only evident 
on the ICP0-null virus infections in primary fibroblasts, and this restriction is 
overcome by the wild-type equivalent of the virus. These results are suggestive 
of an ICP0-dependent mechanism of abrogating TRIM22 restriction. However, 
we demonstrated that TRIM22 is not degraded by ICP0.  
ICP0 has been shown to overcome host immune response by the ICP0-
mediated degradation of TRIM19/PML, which results in the disruption of ND10 
bodies [218]. We hypothesize that ICP0 overcomes TRIM22-mediated restriction 
in a similar mechanism by the disruption of TRIM22 nuclear bodies. One 
potential mechanism is that ICP0 has been shown to localize to centromeres and 
degrade components important for the architecture of centromeres such as the 
centromeric proteins (CENPs), specifically CENP-A, CENP-B and CENP-C [233-
236]. This results in an accumulation of p80-coilin on these damaged 
centromeres [237,238]. TRIM22 nuclear bodies colocalize with Cajal bodies 
containing p80-coilin [221]. TRIM22 and p80-coilin in Cajal bodies have been 
demonstrated to interact in co-immunoprecipitation studies [221]. Therefore, we 
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hypothesize that the presence of ICP0 destabilizes Cajal bodies, and 
subsequently TRIM22 nuclear bodies by promoting p80-coilin relocalization to 
damaged centromeres. This potentially disrupts TRIM22 nuclear bodies in their 
anti-viral functional role. It would be interesting to assess whether ICP0 disrupts 
TRIM22 bodies upon viral infection by immunofluorescence studies in primary 
fibroblasts. 
A potential unbiased approach to assess how ICP0 overcomes the 
TRIM22-mediated restriction of HSV-1 originates from the cell-type specific 
differences we observed. The effect of endogenous TRIM22 in primary 
fibroblasts seems specific to the ICP0-null virus, and the ICP0-rescued viruses 
are capable of overcoming the restriction in high MOI infections. However, in 
HeLa cells, we observed that both the ICP0-null and –rescued viruses are 
capable of overcoming the exogenous TRIM22-mediated effect at high MOIs, 
despite the high levels of protein expression observed upon transfection (Results 
not shown). Instead, the TRIM22-mediated restriction is evident on both the 
ICP0-null and ICP0-rescued viruses at low MOIs in HeLa cells. These cell-type 
differences suggest there is a factor present in primary fibroblasts, but absent in 
HeLa cells, which is crucial for the ICP0-rescued virus’s ability to overcome the 
TRIM22 restriction. A formal experiment assessing TRIM22’s interacting proteins 
in ICP0-null virus versus ICP0-rescued virus infections in primary fibroblasts 
versus HeLa cells could be informative of how ICP0 overcomes the TRIM22-
mediated restriction in these cell types.  
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Overall, it must be noted that the fact that ICP0 overcomes the TRIM22-
mediated restriction of HSV-1 in primary cells is further evidence that the 
herpesviruses have co-evolved with their hosts, and is an additional example for 
the virus-host arms race. Future studies could assess whether there are viral 
proteins parallel to ICP0 in the β- and γ-herpesviruses that can overcome the 
TRIM22-mediated restriction. Potential candidates include the HCMV viral 
proteins, IE1 and pp71, which have been shown to complement the ICP0-null 
HSV-1 [239]. In the case of EBV, the immediate-early protein, BZLF1, has been 
shown to disrupt ND10 bodies much like one of the functions of ICP0 [225]. We 
observed that TRIM22 depletion increased HCMV viral yields by approximately 
4-fold whereas TRIM22 over-expression reduced the efficiency of EBV infection 
in vitro by approximately 3-fold. It must be noted that the viruses used in both 
experiments are equivalent to the wild type, and therefore we hypothesize that 
replication defective versions of these viruses, such as an IE1-null and pp71-null 
HCMV mutant virus or a BZLF1-null EBV mutant virus, are likely to be restricted 
to a greater extent.  
 
4.2.2: TRIM proteins as epigenetic regulators  
 Epigenetic silencing is mediated by factors that either add, remove, read 
and transmit repressive and active histone modifications, DNA methylation and 
acetylation marks on chromatin. This dissertation reports a novel function of 
TRIM22 as an epigenetic regulator of viral genes. This was evidenced in 
conditions of TRIM22 depletion in primary fibroblasts by reduced nucleosomal 
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loading, reduced heterochromatin histone modifications and a trend towards an 
increase in euchromatin histone modifications immunoprecipitated on immediate-
early viral gene promoters.  
The premise for TRIM proteins as modifiers of epigenetic processes exists 
in a subset of the TRIM superfamily of proteins that have a C-terminal PHD-
Bromodomain chromatin interacting module [240]. These TRIM proteins differ 
from TRIM22 in their C-terminal domain, where TRIM22 has a B30.2/SPRY 
domain. Examples of such TRIM proteins include TRIM24 (TIF1α), TRIM28 
(TIF1β) and TRIM33 (TIF1γ). In the context of viruses, TRIM28 corepressor 
complex was shown to mediate retroviral silencing in embryonic stem cells. 
TRIM28 binds the retrovirus primer binding site adjacent to the 5’ long terminal 
repeat and mediates the addition of a dimethyl group on H3K9 [241]. TRIM28 
starts this process by the recruitment of epigenetic silencing factors such as 
histone deacetylase, histone methyltransferase, and members of the 
heterochromatin protein (HP1) family [242]. The authors also hypothesize that 
TRIM28 is targeted to DNA by a Kruppel-associated box zinc finger (KRAB-ZNF) 
protein. Therefore, TRIM28 acts as a corepressor by tethering epigenetic 
effectors to the target DNA site on the retroviral primer binding site, resulting in 
condensed nucleosomes that repress transcription and viral gene expression.  
Although members of this protein family are implicated in viral processes, 
their role in epigenetic regulation of the viral replication cycle is unclear. For 
example, the adenovirus E4orf3 viral gene product targets TRIM33 for 
proteasome-dependent degradation in infection. In addition, both TRIM24 and 
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TRIM33 are reorganized to TRIM19/PML bodies in viral infection suggesting that 
the regulation of these proteins is important for adenoviral replication [243]. It has 
been suggested that the E4-ORF3 viral oncoprotein mediated reorganization 
inactivates p53, TRIM19/PML, TRIM24. MRE11/RAD50/ NBS1 (MRN) tumor 
suppressor complex, enabling small DNA tumor virus mediated dysregulation of 
the cell cycle [244]. Additionally, TRIM24 and TRIM33 were shown to form a co-
repressor complex and cooperatively repress the VL-30 class of endogenous 
retroviruses in the liver [243]. TRIM24 is also shown to be downregulated in the 
increased pathogenicity of a virulent mouse-adapted strain of influenza [245]. 
Additionally, TRIM33 was shown to be upregulated in duck tracheas infected with 
a highly pathogenic or a low pathogenic strains of H5N1 avian influenza A 
viruses [189]. To summarize, there is precedence for the epigenetic role of TRIM 
proteins in viral processes and we add TRIM22 to this list. 
 
4.2.3: TRIM22 as an immune effector 
4.2.3.1: TRIM22 in the adaptive immune system 
 This dissertation does not address the importance of TRIM22 as an 
immune effector, despite the significant amount of literature suggesting its 
importance as an immune gene [246]. The role of TRIM22 in the adaptive 
immune system is closely tied to its expression, as evidenced by: (i) its high 
expression in cells of the lymphoid lineage [247] (ii) its decreased expression 
upon T cell activation [247] and repression during T cell costimulation [99] (iii) its 
association with autoimmune disorders, including the observed higher expression 
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of TRIM22 in lesional psoriatic skin relative to non-lesional psoriatic skin in 
patients [248] (iv) In systemic lupus erythematous (SLE), there was an observed 
hypomethylation of the TRIM22 gene locus in naïve CD4+ T cells from patients 
[249], and TRIM22 expression was decreased in CD4+ T cells in a “disease 
active” state relative to CD4+ T lymphocytes in a “nonactive” state from a SLE 
patient [100].  
It must be noted that it was unclear in these studies whether the role of 
TRIM22 is causative or phenotypic. In the psoriasis study, the authors 
hypothesized that the higher expression of TRIM22 and other anti-viral genes 
resulted in the infrequent cutaneous viral infections observed in psoriatic patients 
[248]. In the SLE study, the authors assumed that the observed downregulation 
of TRIM22 is a marker of CD4+ T cell activation, consistent with the presence of 
activated lymphocytes in an autoimmune lymphocyte phenotype [100]. 
Interestingly, the CD4+ T cells in the SLE “disease active” state also 
demonstrated a higher expression of DNA virus associated proteins, including 
heterogeneous nuclear ribonucleoprotein U-like protein 1 (HNRPUL1), which 
binds an adenovirus oncoprotein and tumor necrosis factor ligand superfamily 
member 14 (TNFSF14), which is the herpes virus entry mediator ligand [100]. 
Although unreported, it would be interesting to assess if the higher expression of 
these DNA virus associated proteins correlates with higher susceptibility to viral 
infections in these patients. 
In conclusion, these findings argue that it is worth addressing TRIM22’s 
role in in vivo implications for herpesviral treatments. Although the anti-viral role 
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of TRIM22 suggests that increasing its expression would be advantageous to the 
host for viral inhibition, the counter argument would be that TRIM22 
downregulation in lymphocytes might be required for T cell activation in order to 
mount an effective immune response. Despite the lack of clarity on the in vivo 
role of TRIM22 in the adaptive immune system, TRIM22 may well be one of 
many factors in the balance between the “good” or anti-viral immune responses 
versus the “bad” or autoimmune disorders. 
 
4.2.3.2: TRIM22 in the innate immune system 
TRIM22 has been shown to have a role in innate immune regulation of 
nuclear factor kappa B (NF-κB) activation, a transcription factor important in the 
induction of inflammatory cytokines [101,102,119]. The reports on TRIM22’s role 
in NF-κB activity suggest that it is a balancing factor between the canonical and 
non-canonical pathways of NF-κB activation. We wished to address whether 
TRIM22’s role in the innate immune system is separable from its role as a 
restriction factor in herpesviral inhibition. 
The canonical pathway of NF-κB activation is regulated by the tumor 
necrosis factor receptor associated factor 6 (TRAF6), an E3 ubiquitin ligase 
(Reviewed in [102]). TRAF6-mediated ubiquitination activates the downstream 
kinase complex composed of TAK1, TAB1 and TAB2. This kinase complex 
phosphorylates the inhibitor of κB (IκB) kinase (IKK) complex. This is mediated 
by TAB2, which binds the polyubiquitin chains of TRAF6, which in turn promotes 
TRAF6 self-ubiquitination and its association with the downstream IKK complex. 
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This results in the subsequent dissociation of IκBα from NF-κB, and thus NF-κB 
activation. TRIM22 has been shown to regulate this pathway by targeting TAB2 
for degradation, and thus it is a negative regulator of the canonical pathway of 
NF-κB activation [102].   
Another group addressed the role of TRIM22 as a positive regulator in the 
non-canonical pathway of NF-κB activation. These studies are conducted by 
over-expression of TRIM22, rather than by co-transfection studies of TRIM22 and 
TRAF6 as reported earlier. In the non-canonical pathway, TRIM22 
phosphorylates IKKα, resulting in the subsequent activation of the NF-κB 
pathway [101]. These results are consistent with the initial report that TRIM22 
overexpression resulted in NF-κB activation in a macrophage cell line [119].  
We hypothesize that HSV-1 hijacks TRIM22’s role in regulating the 
canonical versus non-canonical pathways of NF-κB regulation. It has been 
shown that ICP0 expression exports herpesvirus-associated ubiquitin-specific 
protease (HAUSP) or ubiquitin-specific protease 7 (USP7), from the nucleus to 
cytoplasm where USP7 binds and deubiquitinates TRAF6 and IKKγ, thus 
inhibiting the NF-κB response. Hence, the presence of ICP0 in a wild-type virus 
infection would be reminiscent of TRIM22’s role in the canonical pathway or 
where TRIM22 is an inhibitor of the NF-κB response. Conversely, in the absence 
of ICP0, TRIM22 potentially mediates NF-κB activation via the non-canonical 
pathway resulting in the production of NF-κB responsive anti-viral cytokines. In 
fact, TRIM22 has been hypothesized to interact with USP7 in a yeast two-hybrid 
screen under non-viral conditions [250]. It would be interesting to assess if 
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TRIM22 sequesters USP7 in the nucleus, preventing the USP7-mediated 
inhibition of the NF-κB response observed in the presence of ICP0.  
Consistent with this hypothesis, we observed that TRIM22 depletion 
reduced basal levels of NF-κB cytokines, such as IL6 transcript levels in 
untreated primary fibroblasts (Results not shown). We also observed that 
TRIM22 depletion reduced the induction of IL-1beta and IL-18, other NF-κB 
responsive cytokines by a few fold in the ICP0+ or 7134R virus infection (Results 
not shown). There was no difference observed upon ICP0- or the 7134 virus 
infection (Results not shown). However, the more conclusive experiment is to 
determine whether the rescue in ICP0-null viral yields observed under TRIM22 
depletion is abrogated upon activating the NF-κB pathway. Therefore, the role of 
TRIM22 in regulating the NF-κB pathway in HSV-1 infection would require further 
elucidation. 
Interestingly, there may be a role for TRIM22 as an innate immune 
effector in RNA virus infections. In preliminary results, we observed an eight-fold 
reduction in IFNβ induction upon TRIM22 depletion in primary fibroblasts relative 
to control depletion in Sendai virus infection, an RNA virus (Results not shown). 
These preliminary results suggest that the TRIM22-mediated effect in the 
inhibition of RNA viruses may be dependent on its role as an innate immune 
effector and is potentially separable from its mechanism of herpesvirus inhibition.  
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4.2.4: TRIM22 as a cell cycle mediator in oncogenesis 
 There is evidence in the literature that suggests that TRIM22 is involved in 
the progression of the cell cycle [251]: (i) TRIM22 is downregulated in breast 
cancer [252] (ii) its overexpression reduces the clonogenic growth of U937 cells, 
a leukemic cancer cell line [118] (iii) it is downregulated upon maturation of 
hematopoietic stem cells into the erythroid lineage [103] (iv) it associates with the 
centrosome regardless of the cell cycle phase in one report [117], but TRIM22 
nuclear bodies begin to form in the G0/G1 phase of the cell cycle and are 
dispersed in the S phase in HeLa cells [221] (iv) its lower expression in Wilms 
tumors, a renal neoplasm, has also been associated with fatality [104,105] and 
its reduced expression has been associated with neuroblastoma tumorigenesis 
[253].  
Although it is well-known that the small DNA tumor viruses such as SV40 
and the human papilloma virus require an S-phase environment to support viral 
replication, herpesviruses prevent cell cycle progression into the S phase during 
lytic replication. HSV-1 has been shown to block cellular DNA synthesis [254], 
HSV-1 ICP0 arrests cell cycle progression from G1 into the S phase [255-257] 
and ICP27 is also important in HSV-1 mediated growth arrest [258]. CMV has 
been shown to inhibit cell cycle progression from G1 to S phase, despite 
encoding proteins that elicit cell cycle progression such as IE1 and IE2 (reviewed 
in [258]). In EBV infection, the switch from latent replication to lytic replication 
results in a G0/G1 arrest (reviewed in [258]). Therefore, there is precedent for the 
importance of cell cycle arrest in herpesviral replication. We speculate that the 
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interaction between TRIM22, the herpesviruses and the cell cycle could begin to 
be elucidated by assessing viral yield assays in synchronized cells, and in 
growth-arrested cells.   
As we mentioned previously, TRIM22 potentially has a role in viral latency. 
The EBV latent membrane protein-1 (LMP-1), which is required for EBV latency, 
is upregulated in exogenous TRIM22 expression [112]. TRIM22 also has been 
demonstrated to be upregulated by the KSHV LANA protein [111]. Although there 
have been no direct experiments addressing the importance of TRIM22 in 
latency, it would be interesting to address whether the γ-herpesviruses such as 
EBV hijack the cell biological role of TRIM22 in cell proliferation in mediating 
oncogenesis post establishment of viral latency.  
 
4.2.5: Is TRIM22 genotype a predictor of host herpesviral susceptibility? 
The TRIM5 and TRIM22 gene neighbors have been shown to be 
important in restricting lentiviruses [259,260]. Additional data suggests that TRIM 
proteins are important for restricting viruses outside of the lentivirus family, 
particularly TRIM22 (Reviewed in [153]). We demonstrated in this dissertation 
that TRIM22 inhibits the herpesviruses and also showed that the seven different 
TRIM22 haplotypes identified by our collaborators vary in their degree of HSV-1 
restriction. We also show that individuals homozygous for the presence of SNPs 
encoding an arginine at position 242 in the linker L2 domain, or homozygous for 
an aspartic acid at position 155 in the coiled-coil domain are potentially more 
restrictive to HSV-1 and EBV, respectively. We demonstrate that the frequency of 
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individuals homozygous for the more “restrictive” SNPs varied across Caucasian, 
Yoruba, Japanese and Han Chinese ethnic groups.  It would be interesting to 
assess whether the TRIM22 haplotypes that a person encodes correlate with 
individual susceptibility to herpesviral infection/disease. Further studies 
assessing the TRIM22 genotypes of individuals and their herpesviral titers at 
early time points post acquisition and measurement of herpesviral loads post 
reactivation as a correlate of herpesviral disease may be potential avenues of 
interest.  
The haplotypic diversification observed at the TRIM22 gene locus, 
combined with additional studies addressing the role of the different TRIM22 
haplotypes in altering the degree of susceptibility to other relevant viruses in the 
human population including human immunodeficiency virus-1 (HIV-1), hepatitis B 
virus (HBV), hepatitis C virus (HCV), encephalomyocarditis virus (EMCV) and 
influenza A virus (IAV) will further broaden the spectrum of evidence for the 
importance of TRIM22 as an anti-viral factor.  
In conclusion, we demonstrated that TRIM22 is a novel restriction factor of 
herpesviruses with a focused analysis on the mechanism of TRIM22-mediated 
restriction in HSV-1 replication. The genetic variation in TRIM22 is a potential 
marker for the differences in herpesviral susceptibility between individuals and 
across ethnic groups, and is another example of the arms race between hosts 
and viruses.  
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